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Chapter 1. 
General introduction 
 
1.1. Cancer 
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. One in 
eight deaths worldwide is due to cancer.
1
 Worldwide, cancer causes more deaths than AIDS, tuberculosis, 
and malaria combined. When countries are grouped according to economic development, cancer is the 
leading cause of death in developed countries and the second leading cause of death in developing countries 
(Table 1-1). The burden of cancer is increasing in step with the aging of the population. In Japan, one of the 
world’s fastest aging societies, cancer is the top cause of mortality, accounting for 29% of deaths in 2013.2 
Population aging is quickly progress in the developing countries. Thus, cancer is a global health problem that 
should be put in serious effort to tackle.  
 
1.1.1. Principal methods of curing cancer 
Principal cancer therapies are surgery, radiotherapy, and chemotherapy. Surgery has been used to remove all 
of localized tumors or reduce the size of large tumors. Radiotherapy is the medical use of ionizing radiation 
to kill cancer cells in the treatment area. Chemotherapy is the use of antitumor drugs to treat cancer. These 
drugs not only kill cancer cells but also keep them from growing and spreading. Among of these treatments, 
surgery and radiotherapy achieve good therapeutic effect for localized tumors. However they are not 
effective against metastatic cancer and inadaptable to leukemic disease. In contrast, chemotherapy has the 
potential to be adaptable to metastatic cancer and leukemic disease, since anticancer drugs are carried to the 
whole body via the blood stream. Furthermore chemotherapy is given before or after surgery and/or 
radiotherapy to reduce tumor size and inhibition of metastasis, so chemotherapy has been to play the 
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important role in curing cancer. However chemotherapy has a low cure rate than other two methods, and 
anticancer drugs sometime would also affect and kill normal cells and induce serious side effects such as hair 
loss, mouth sores, nausea, and vomiting. Therefore to improve the cure rate and reduce the side effects, 
developments of new anticancer drugs with novel antitumor mechanism that has high selectivity for cancer 
has been strongly anticipated. 
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1.1.2. Anticancer drugs from natural products 
More than 200 antitumor drugs have been used in clinical practice. Among these antitumor drugs, 
small-molecule drugs account for approximately 80%, and natural inspired drugs (i.e., natural products, 
derived from natural product, and totally synthetic drugs but the pharmacophore is/was from natural product) 
constitute over 70% of small-molecule drugs.
3
 This fact suggests that natural products are important for 
development of antitumor drugs. Diversity of the complex structure with the chirality and activities of 
natural products have promise as a good source to investigate for antitumor agents which have novel mode of 
action. Historically, drugs were discovered from plants and fungi as natural medicines and others. Attention 
is currently focused on natural products which are derived from marine organism. Many marine organisms 
such as sponge, sea squirt, nudibranch and microorganism, keep a store of bioactive substances as chemical 
defenses and a lot of bioactive secondly metabolizes have been found from marine organism. Among them, 
many compounds exhibit antitumor activity. Examples of marine antitumor compounds classified as a typical 
mode of action are described below (Figure 1-1). 
 
Enzyme inhibitor 
Bryostatin-1
4
 is a protein kinase C (PKC) inhibitor, isolated from the bryzoan Bugula neritina. PKC is one of 
the families of serine/threonine-specific protein kinase, and plays important roles in several signal 
transduction cascades involving cell growth, malignant alteration, and others.
5
 Therefore, PKC inhibitors 
have a potential as antitumor agents. 
Aeroplysinin
6
 is a bromotyrosine derivative which is included in the sponge Verongia aerophoba. It prevents 
angiogenesis that is important for cancer growth by inhibition of protein tyrosine kinase.
7
  
  
DNA replication inhibitor 
Ecteinascidin 743 (ET743)
8
 is a DNA-alkylating agent and isolated from the sea squirt Ecteinascidia 
turbinate. DNA-alkylating agents interfere with a DNA replication by alkylation of DNA. Since cancer cells 
4 
 
that undergo cell division frequently have great sensitivity for DNA lesion, the agents exhibit antitumor 
activity.  
 
Spindle poison 
Many marine natural products interact to tubulin as spindle poison. Historically, tubulin is one of the most 
important targets of antitumor agents, so the detail of tubulin and tubulin-interactive agents is described in 
next section.  
 
 
 
         
 
 
 
Figure 1-1. Antitumor agents from marine origin 
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1.2. Microtubule (Tubulin) 
Microtubule is one of the cytoskeletons and formed by polymerization of - and β-tubulin heterodimer 
(Figure 1-2).
9
 Microtubules have several key roles that are important for cell proliferation, trafficking, 
signaling, and migration in eukaryotic cells. Especially, microtubules form mitotic spindle and play a 
primary role in the division of chromosome at metaphase. Since this process is controlled by dynamics of 
tubulin assembly and disassembly, inhibition of tubulin disrupts cell division and causes cell death by 
apoptosis. Therefore, tubulin is an important antitumor target along with DNA, and tubulin-interactive agents 
have been studied for a long time. 
 
 
 
 
Figure 1-2. (a) Structure of /-tubulin heterodimer; (b) The dynamics of microtubule 
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1.2.1. Tubulin-interactive agents 
Paclitaxel (taxol),
10
 which were isolated from Taxus brevifolia, and vinblastine,
11
 which were isolated from 
Vinca rosea, are famous tubulin-interactive agents, and they have been used as anticancer drugs in clinical 
practice for a long time (Figure 1-3). Colchicine is also a well-known tubulin-interactive agent while it has 
not been clinically used. Tubulin-interactive agents are often classified into two main groups, 
microtubule-stabilizing and microtubule-destabilizing agents. Microtubule-stabilizing agents enhance 
tubulin-polymerization and include the taxans (paclitaxel and docetaxel
12
), epothilone A,
13
 discodermolide,
14
 
and others. Many microtubule-stabilizing agents bind to the same or to overlapping binding-site of paclitaxel. 
Microtubule-destabilizing agents inhibit tubulin-polymerization and include the vinca alkaloids (vinblastine 
and vincristine
15
), colchicine, halichondrine B,
16
 dolastatine 10,
17
 and others. These microtubule-destabilizing 
agents bind to the same or similar binding sites of vinblastine or colchicine. Meanwhile, several 
tubulin-interactive agents, such as laurimalide
18
 and peloruside A
19
 bind to novel site of tubulin.  
Tubulin-interactive natural products have diversity and complex structures. In general they are present 
in only minute amount in natural organisms which are uncultivable. These may become the serious problem 
to develop in clinical. It is noteworthy that the identification and investigation of tubulin-interactive agents 
were nonetheless ongoing. For example, research team of Eisai Research Institute and the Kishi group 
developed eribulin,
20
 which approved as a new antitumor drug for metastatic breast cancer, through the 
studies on halichondrin B (Figure 1-4).  
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Figure 1-3. Tubulin-interactive agents  
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Figure 1-4. Anticancer drug Eribulin was an analogue of halichondrin B. 
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1.3. Target identification 
Identification of target biomolecules and study on the mode of action of a bioactive compound are important 
for the development of new drugs and contribute to the elucidation of biological system such as signal 
pathway and protein-protein interaction. Recent technological developments in high-throughput screening 
and spectroscopic analysis for minute compounds have enabled to discover new bioactive small molecules. 
However target biomolecules and the mode of action of most of such small compounds are still unclear.  
Identification of biomolecules is performed using various approaches.
21
 If the target is a known 
biomolecule, it can be predicted by cancer cell line screening, bioassays for typical cancer targets, or 
computational inference. However, in the case that a compound interacts with unknown target biomolecules 
and/or has a novel mode of action, identification of target molecules require genetic approach or direct 
biochemical methods. Genetic approach identifies the target proteins by investigating the genetic 
modification which changes the sensitivity of a compound. Direct biochemical method is the approach to 
observe the interaction with target proteins by using labeling compounds called chemical probes. This 
approach does not require the use of genetic engineering and has been often used for the target identification 
of natural products. The detail of the method is described in the next section.   
 
1.3.1. Chemical probes 
A chemical probe is composed of a natural product as a ligand, tag/label groups, and a linker moiety which 
connects a ligand and tag/label groups. The chemical probe interacts with the target molecules of its ligand 
and is able to specifically label these. Target proteins that were labeled by the chemical probe can be detected 
and purified by using the tag/label group of the chemical probe to identify the target molecules. One of the 
frequently used tag/label groups is biotin. Biotin has a strong and specific interaction with avidin, and 
various avidin derivatives, such as avidin-resin and horse radish peroxidase (HRP) conjugate avidin for 
chemiluminescence detection, are commercially available (Figure 1-5). Therefore, biotin is one of the most 
commonly used group for target identification. The linker group separates the tag/label group from the ligand 
10 
 
in order for the tag/label group not to affect the interactions between the ligand and its target proteins. The 
linker group also prevents the ligand from affecting the interaction between the tag and its target. PEG linker, 
peptide linker and alkyl chain linker are commonly used as the linker group.  
 
 
Figure 1-5. Structures of biotin and biotin-avidin complex (PDB code:2AVI) 
 
In the case that the interaction with target proteins is weak or the amount of target proteins is minute, 
photolabeling experiments are useful. Chemical probes that have a photoreacting group, such as 
benzophenone, diazirine and azide, are called photoaffinity probes (Figure 1-6). Since photoaffinity probes 
covalently bind to adjacent proteins, the connections between the ligand and its target proteins are not 
cleaved even if the target proteins are denatured and digested. Therefore, by using photoaffinity probes, 
target protein is detectable by Western blotting analysis, and the binding site of ligands can be determined.  
 
 
Figure 1-6. Typical photoreacting groups. 
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1-4. Aplyronine A 
1.4.1. Isolation and biological activities of aplyronine A 
As described in section 1.3, a lot of natural products that exhibit interest activities were discovered, however 
many of their modes of action are still unclear. Aplyronine A (ApA, 1) is one of the such natural products. 
ApA is a 24-membered macrolide, which was isolated in 1993 from the Japanese sea hare Aplysia kurodai by 
Yamada and co-workers (Figure 1-7).
22
 ApA has C24-34 side-chain moiety which bears a terminal N-methyl 
enamide group and two unique amino acid portions (N,N,O-trimethylserin and N,N-dimethylalanine) as 
structural features. ApA displays strong cytotoxicity against HeLa S3 cells. Furthermore, ApA exhibit potent 
antitumor activities against various mouse xenograft models (Table 1-2). Interestingly, ApA is shown to not 
affect the target molecules of known antitumor agents, such as DNA, microtubule, and cycle regulating 
enzymes.
23
 In 1996, Karaki and co-workers ascertained that ApA inhibits the polymerization of actin by 
forming a 1:1 complex with actin.
24
 Thus ApA is expected to be a new type of anticancer agent which 
interacts with actin. 
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Figure 1-7. Structure of aplyronine A (1)  
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1.4.2. Actin 
Actin is a cytoskeletal protein as with tubulin. Actin is one of the most abundant proteins in eukaryotic 
cells, and exists as a dynamic equilibrium mixture between globular actin (G-actin, monomer) and fibrous 
actin (F-actin, polymer) in cells (Figure 1-8). Microfilaments composed of F-actin, controlls several cell 
functions, such as cell muscle contraction, cell motility, division of cytoplasm, and adhesion. Almost 
actin-interactive agents inhibit the division of cytoplasm to lead multinucleated and finally induce apoptosis. 
Thus, actin is expected to be a new target of antitumor drug. However the study on the actin-interactive 
agents is less-advanced to develop actin-targeting antitumor drugs.  
Many actin-targeting agents have been reported (Figure 1-9). Phalloidin
25
 and jasplakinolide
26
 enhance to 
polymerize actin, while latrunculin A (LatA)
27
, bistramide A
28
, and pectenotoxin A
29
 inhibit the 
polymerization of actin. Many macrolides also depolymerize F-actin, which involve kabiramides,
30
 
micarolide B (MyB),
31
 reigispongeolide A,
32
 and iejimalide A.
33
 All of these macrolides have similar side 
chain structure to ApA in contrast with diversity of macrolactone moiety. Thus it is inferred that the side 
chain structure is important for actin-binding ability. Actually X-ray crystal structures of kabiramide C-actin 
complex and reigiapongeolide A-actin complex were reported,
34
 which showed that their side-chain moieties 
insert into the cleft between subdomains (SD) 1 and 3 of actin. It is suggested that ApA also interacts with 
actin by using its side chain moiety. 
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Figure 1-8. Actin exists in equilibrium between G-actin and F-actin in cells. 
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Figure 1-9. Actin-targeting agents. 
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1.4.3. Structure-activity relationships of ApA 
Total synthesis of ApA has been accomplished in 1996, and structure-activity relationships (SAR) study of 
ApA have been performed. For example, ApA side chain analogue 3 exhibited one-tenth of 
actin-depolymerization activity of ApA, while the macrolactone analogue 4 showed no activity (Table 1-3). It 
was suggested that side chain moiety of ApA has a key role of actin-depolymerizing activity. In addition, 
fluorescent photoaffinity probe 5 possessing the side chain moiety of ApA as ligand was synthesized (Figure 
1-10), and found to photolabeled actin.
35
 Photolabeling of actin with probe 5 was inhibited by competition of 
ApA or MyB. On the other hand, LatA, that bind to actin at the ATP binding site between SD 2 and 4, was 
not able to inhibit the labeling of actin. These results indicated that ApA directly bind to actin not at LatA 
binding site but at MyB binding site. 
The side chain analogue 3 did not exhibit cytotoxicity, which suggested that there was poor correlation 
between potent cytotoxicity and actin-depolymerizing activity of ApA. Structures and bioactivities of ApA 
and seven minor congeners of ApA were shown in Table 1-3. Cytotoxicity of the congeners which have 
serine ester moiety at C7 (aplyronines D, E, F and G) are comparable to or better than ApA. In contrast, 
congeners which have serine ester moiety at C9 (aplyronine B and H) exhibit one-tenth cytotoxicity of ApA. 
Furthermore, cytotoxicity of aplyronine C (2), which has no serine ester moiety, decline to one-thousandth. 
These results suggested that serine ester moiety of ApA play a key role for its potent cytotoxicity. On the 
other hand, aplyronines A-C exhibit comparable actin-depolymerizing activity. Therefore serine ester moiety 
does not affect the actin-depolymerizing activity. Further SAR study revealed that not only trimethylserine 
ester moiety but also conjugated double bond and two hydroxyl group are also important for cytotoxicity and 
have little effect for actin-depolymerizing activity. However, macrolactone analogue 4, which has these 
moieties that are important for cytotoxicity, exhibits neither cytotoxicity nor actin-depolymerizing activity. 
Thus the actin-binding activity is also a necessarily condition for the potent cytotoxicity of ApA but is not a 
sufficient condition.  
  
17 
 
In 2006, Hirata and co-workers reported the X-ray crystal structure of actin-ApA complex (Figure 
1-11).
36
 The X-ray analysis revealed that ApA interacts with the hydrophobic cleft between SD 1 and 3 of 
actin by using its side chain. On the other hand, trimethylserine ester of ApA protrudes from actin surface 
and does not affect interaction with actin. From these findings, it is probable that ApA binds to other 
biomolecules and the trimethylserine ester moiety play an important role in binding to these biomolecules. 
Therefore, the author aimed to clarify the mode of action of ApA through the identification of the other 
biomolecules that bind to ApA.  
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Figure 1-10. Fluorescent photoaffinity probe 5 with ApA side chain. 
 
 
 
 
 
Figure 1-11. (a) Structure of the actin-ApA complex; (b) the same complex rotated by 90°. 
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Chapter 2. 
Identification of the New Target Proteins of Aplyronine A 
 
 
Abstract 
To identify the target proteins of an antitumor macrolide aplyronine A, biotin probes of aplyronines were 
synthesized. By using biotin probes of aplyronines A and C, Arp2 and 3 (actin-related proteins) were purified 
from cell lysate along with actin. However aplyronine photoaffinity probes were found not to covalently bind 
to Arp2 or Arp3. Thus, actin-related proteins might indirectly bind to ApA as the ternary adducts of the 
actin/ApA complex or through the oligomeric actin. Through in situ photolabeling experiments with 
photoaffinity probes of ApA, tubulin as well as actin were specifically labeled. Since ApA competitively 
inhibited the labeling of tubulin by photoaffinity probes, tubulin might be the new target protein of ApA. 
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2.1. Introduction 
Aplyronine A (ApA) is a marine natural product that shows potent antitumor activity.
1
 However the 
molecular targets and mechanisms of action of ApA have remained unclear. The author has attempted the 
identification of new target proteins of ApA by chemical probe approach. Identification of target 
biomolecules by using chemical probes requires three steps: synthesis of chemical probes, purification of 
binding proteins, and identification of purified proteins.  
Syntheses of chemical probes which maintain the activities of original natural products are important. 
However, there is no general answer to design chemical probes due to the diversity of structure and property 
of natural products. Thus we have to consider the best way for each original compound. In general, to 
develop active chemical probes, structure-activity relationships (SAR) studies are important. Also we need to 
verify the bioactivities of synthetic derivatives.   
With the desired chemical probes in hand, we can attempt the purification of binding biomolecules with 
chemical probes. Purification of target proteins also involved several optimizations, such as preparation and 
labeling conditions of proteins. After target biomolecules are purified, we should confirm the specificity of 
interaction of biomolecules with the ligands. Generally, competitive experiments using excess ligands and 
the control experiments with negative probe are useful to confirm the specificity of binding property of the 
probes. 
If we successfully purify target proteins, next we attempt the identification of these proteins. Protein 
identification can be performed by using mass spectrometry analysis, such as peptide mass fingerprinting 
(PMF) analysis
1
 and de novo sequence analysis. For identification of proteins by PMF analysis, observed 
mass values of digested peptide are compared with the theoretical mass data from worldwide database.  
In this chapter, the various biotin-conjugated aplyronine derivatives are synthesized and used for the 
purification and identification of new target proteins of aplyronine A. 
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2.2. Synthesis of the biotin derivatives of ApA 
2.2.1. Design of ApA-biocytin and ApA-bio  
The design of a chemical probe is important to identify the target proteins of ApA. Previous SAR studies of 
ApA revealed that both side-chain moiety and macrolactone moiety of ApA are important, and it is proposed 
that ApA interacts with two or more target proteins. Therefore it is difficult to expect which substituent group 
can be modified without significant loss of activity. Although the total synthesis of ApA was already 
accomplished, it is still difficult to synthesize various ApA derivatives by the synthesis. Therefore the author 
considered that chemical probes would be derivatized from natural ApA.  
It has been suggested that the N-methyl enamide moiety, which is common to various 
actin-depolymerizing macrolides, is important for their cytotoxicities.
2
 On the other hand, in 1998, Watabe 
and co-workers reported the derivative of kabiramide D (KaD), an actin-depolymerizing macrolide that 
possesses a similar side-chain structure to ApA (Figure 2-1).
3
 The derivative of KaD was synthesized by 
acidic hydrolysis of the N-methyl enamide moiety, which is a common structure to ApA, followed by 
reductive amination with biocytin. Although the cytotoxicity and actin-depolymerizing activity of the 
biocytinylated KaD were not reported, they reported that it maintained the actin-binding activity.  
Because there is a space inside the 1,3-cleft of the actin molecule (Figure 2-2), the author anticipated that 
ApA could be modified at C34 without a significant loss of activity by elongating a tethered biotin moiety 
with hydrophilic groups. Therefore ApA-biocytin probe (ApA-biocytin, 6) and ApA-PEG linked biotin probe 
(ApA-bio, 7) were designed (Figure 2-3). 
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Figure 2-1. Biocytinylated kabiramide D. 
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Figure 2-2. Binding mode of ApA to actin (PDB code:1WUA). 
 
 
 
 
 
Figure 2-3. Structures of ApA biotin probes. 
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2.2.2. Synthesis of ApA-biocytin and ApA-bio*   *These experiments were performed by co-workers. 
ApA-biocytin and ApA-bio were synthesized from ApA (Scheme 2-1). Acidic hydrolysis of 1 afforded the 
C34 aldehyde 8.
5
 Reductive amination of 8 with biocytin (9) gave ApA-biocytin (6) (24%). The coupling 
reaction of 8 with EZ-Link biotin-PEG4-hydrazide gave ApA-bio (7) (38%). For comparison, model biotin 
probe (model-bio, 10) was also prepared from the 3-phenylpropionaldehyde. 
 
 
 
Scheme 2-1. Synthesis of ApA biotin probes. 
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2.2.3. Biological activity of ApA-biotin derivatives 
The cytotoxicities and in vitro actin-depolymerizing activities of ApA analogues and model compounds were 
compared to those of ApA (Table 2-1). ApA-biocytin (6) was found to be 1500 times less cytotoxic than ApA 
(IC50 15000 pM), whereas ApA-bio (7) was only approximately 10 times less active than ApA (IC50 96 pM). 
ApA-biocytin (6) bears a carboxyl group, which may influence its ability to permeate into living cells or give 
it lower affinity for target molecules, thus causing a decrease in cytotoxicity. Meanwhile, ApA-biocytin (6) 
and ApA-bio (7) showed potent actin-depolymerizing properties, which were comparable to those of natural 
ApA. In contrast, both biocytin (9) and model-bio (10) which lack the whole parts of ApA, did not exhibit 
both cytotoxicity and actin-depolymerizing activity.  
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2.2.4. Labeling experiments with Actin  
The biotinylated ApA derivatives were then examined to determine their specificities for binding to actin. 
When the binding proteins were competitively eluted by an excess ApA, only the actin that were attached to 
ApA-biocytin (6) or ApA-bio (7) were eluted (Figure 2-4a). In contrast, actin was eluted in all lanes by 
boiling the resins in SDS buffer (Figure 2-4b). Thus, considerable amounts of actin were nonspecifically 
absorbed to the hydrophobic agarose resin because of the presence of the lipophilic parts of the actin 
molecule (i.e., the SD 1,3-cleft). Despite this behaviour, resin-bound ApA-biocytin (6) and ApA-bio (7) were 
found to exhibit high affinity for actin and to have the same binding properties as ApA. 
 
 
 
 
 
 
Figure 2-4. Interaction of biotinylated ApA derivatives with actin. Actin in G-buffer was treated with 6, 7, 9, 
10 or DMSO that were preloaded on NeutrAvidin agarose. Binding actin was eluted a) by treatment with 5 
µM ApA or b) by boiling in SDS buffer, and detected with silver stain. 
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2.2.5. Design of Aplyronine photoaffinity biotin probes 
Since ApA-bio (7) maintained the activities of ApA, it was revealed that the N-methyl enamide moiety is a 
good substituent for elongating the linker to synthesize their chemical probes. Thus ApA photoaffinity biotin 
probe (ApA-PB, 11) that possesses a diazirine group as a photoaffinity group, was designed based on the 
design of ApA-bio (7). Since ApA-PB (11) can bind covalently, a weak interaction between ApA and 
intracellular proteins can be detected and the binding mode of target proteins with ApA-PB (11) can be 
analyzed. Furthermore, ApC photoaffinity biotin probe (ApC-PB, 12) that has ApC instead of ApA, was also 
designed as a negative control. 
 
 
 
 
Figure 2-5. Structures of aplyronine photoaffinity biotin probes 
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2.2.6. Synthesis of alkoxyamine 19 
Alkoxyamine 19 that has aryl diazirine moiety and biotin group was synthesized (Scheme 2-2). 
Condensation of bis[2-(3-aminopropoxy)ethyl]ether with (+)-biotin N-hydroxysuccinimidyl ester gave amine 
13
6
 (67%). Condensation of carboxylic acid 14
7
 with amine 13 yielded amide 15 (74%). Deprotection of the 
Boc group of amide 15 followed by the coupling with succinyl ester 17
8
 in the presence of DIPEA gave the 
amide 18 (82%). Deprotection of the Phth group in 18 yielded alkoxyamine 19 (quant.). 
 
 
 
Scheme 2-2. Synthesis of alkoxyamine 19 
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2.2.7. Synthesis of ApA-PB and ApC-PB*        * Synthesis of ApC-PB was performed by co-workers. 
ApA-PB (11) and ApC-PB (12) were synthesized from ApA (Scheme 2-3). Acidic hydrolysis of ApA 
afforded the aldehyde 8. The oximation reaction of 8 with alkoxyamine 19 gave ApA-PB (11) (71%). Due to 
the scarcity of ApC from natural sources (e.g., 3 × 10
− 7
% yield based on wet wt), ApC was prepared from 
the conversion of ApA. Methanolysis of ApA with 0.1% triethylamine preferentially cleaved the 
trimethylserine ester to give ApC in 41% yield (with 38% of recovered ApA). Subsequent acidic hydrolysis 
of ApC followed by condensation with alkoxyamine 19 gave ApC-PB (12) (41%). 
 
 
 
Scheme 2-3. Synthesis of ApA-PB (11) and ApC-PB (12) 
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2.2.8. Biological activity of Aplyronines photoaffinity biotin probes 
Biological activities of aplyronine photoaffinity biotin probes were compared with those of natural 
compounds (Table 2-2). ApA-PB (11) showed potent cytotoxicity against HeLa S3 cells (IC50 1.2 nM), 
whereas the ApC-PB (12) was 260 times less cytotoxic than ApA-PB (IC50 310 nM).  
Since the diazirine group is degraded by UV irradiation, we did not perform actin-depolymerizing assay, 
which needs UV irradiation. Instead, ApA-PB (11) was shown to potently inhibit F-actin sedimentation, 
which was confirmed by ultracentrifugation (Figure 2-6). F-actin was prepared by polymerization of G-actin 
(3 M) in the presence of MgCl2, followed by treatment with ApA or ApA-PB (11) (3 µM) to depolymerize 
the F-actin. After ultracentrifugation (150,000×g), the proteins contained in the supernatant (S) and the 
precipitate (P) were analyzed by SDS-PAGE analysis. Actin did not polymerize without the MgCl2 and not 
precipitate by ultracentrifugation, thus protein bands were mostly detected in the S fraction (lane 1). When 
the MgCl2 was added, actin was polymerized and precipitated by ultracentrifugation, thus protein bands were 
detected in the P fraction (lane 2). Treatment with ApA caused complete depolymerization of F-actin and the 
protein bands were detected in the S fraction (lane 3). Similarly, upon treatment with ApA-PB (11), the 
protein bands were also mostly observed in the S fraction (lane 4), which established that ApA-PB (11) had 
an actin-depolymerizing property while the activity was slightly weaker than ApA.  
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Figure 2-6. F-actin sedimentation assay. After F-actin was incubated with ApA or ApA-PB (11), the 
remaining F-actin was precipitated by ultracentrifugation. The proteins in the supernatant (S) and the 
precipitate (P) were detected by CBB stain.  
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2.3. Purification and identification of target proteins from cell lysate 
 
2.3.1. Purification and identification of target proteins by ApA-bio 
The pull-down assay with ApA-bio (7) in the whole cell lysate of HeLa S3 was conducted (Figure 2-7). To 
minimize interference with intrinsic biotin-binding molecules, NeutrAvidin agarose was pretreated with an 
excess amount of ApA-bio (7), on which the lysate of HeLa S3 cells was loaded. After incubation, the resin 
was washed with 0.1% Triton PBS. The binding proteins were eluted by boiling in SDS buffer or 
competition of ApA, and detected with silver stain (Figure 2-8).  
 
Figure 2-7. Outline of the pull-down assay. 
 
When the binding proteins were eluted by boiling, four bands with molecular masses of 40, 43, 47 and 
200 kDa were clearly detected along with several nonspecific bands (Figure 2-8, a). These four bands were 
identified as miyosin II heavy chain (200 kDa), actin related proteins 2 and 3 (Arp2 and 3, 40 and 47 kDa), 
and actin (43 kDa), respectively, through the PMF. To confirm the identification of PMF, immunoblotting 
analysis were carried out. Only in the presence of ApA-bio (7), myosin II, actin, Arp2 and Arp3 were 
detected with each moleculer masses of 200 kDa, 43 kDa, 40 kDa and 47 kDa (Figure 2-8, b–e), therefore 
the PMF analysis result was correct. 
 To confirm the specificity of interaction of these proteins with ApA-bio (7), same competitive 
experiments were carried out except the elution condition from the resin. When binding proteins were 
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competitively eluted by treatment of excess ApA (Figure 2-9), actin (43 kDa) were clearly detected. Arp2 (40 
kDa) and Arp3 (47 kDa) were also slightly detected, but myosin II (200 kDa) was not detected. Thus, 
ApA-bio (7) may specifically interact with Arp2 and Arp3 as well as actin, but not with myosin II. Since 
myosin II is known to bind to F-actin, this protein may interact with the abundant actin that nonspecifically 
bound to the resin. 
To further analyze the interaction between ApA-bio (7) and actin, biotinylated proteins were detected 
with a HRP conjugated streptavidin (Figure 2-10). Upon treatment with ApA-bio (7), a weak band 
corresponding to actin (43 kDa) was observed, along with nonspecific bands (120 and 74–72 kDa, biotin 
carboxylase). In the same experiments, compounds derived from ApA-bio (7), which did not bind to proteins, 
were detected in the region of the lowest molecular weight (< 10 kDa). Meanwhile, the amounts of bound 
actin that were eluted by boiling of resins were mostly the same as those by the ApA elution (Figures 2-8 and 
2-9, lane 1). These results suggested that most actins bound to ApA-bio (7) were competitively eluted by 
ApA, and that binding property between ApA-bio (7) and actin was non covalent, such as hydrogen bond and 
van der Waals interaction. 
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Figure 2-8. SDS-PAGE analysis of the proteins purified from HeLa S3 cell lysate by pull-down assay. 
Affinity-purified proteins were eluted from NeutrAvidine-resin by boiling and were detected a) with silver 
stain or by immunoblotting analysis using b) anti-myosin II, c) anti-actin, d) mixtures of anti-Arp2 and Arp3 
or e) anti-Arp3, respectively. 
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Figure 2-9. SDS-PAGE analysis of the proteins eluted by the competitive elution with ApA. Proteins were 
detected with silver stain.  
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Figure 2-10. Detection of biotinylated proteins from HeLa S3 cell lysate. Proteins were purified by 
pull-down assay using ApA-bio (7), eluted by the boiling from NeutrAvidin-resin, and detected with HRP 
conjugate streptavidin.  
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2.3.2. Arp2/3 
Arp2 and Arp3 are the key proteins of the Arp2/3 complex (Figure 2-11), which binds to the sides of an 
existing actin filament and initiates growth of a new actin filament to form branched-actin-filament 
networks.
9
 The amino acid sequences and three-dimensional structures of Arp2 and Arp3 are highly similar 
(46% and 36% identity) to those of monomeric actin (Figure 2-12). The secondary structure around the 
ApA-binding sites of actin is closely similar to those of Arp2 and Arp3. Moreover, the remaining 
components of the Arp2/3 complex, Arp2/3 complex subunit 1-5 (ARPC1–5, 16–40 kDa), were not purified 
by the pull-down assay with ApA-bio (7) (see Figure 2-9). Thus, it was suggested that ApA may bind to Arp2 
or Arp3 to give 1:1 complexes, as with the actin-ApA complex. Since it was difficult to further analyze the 
interaction of ApA with Arp2 and Arp3 by ApA-bio (7), their detail interactions were analyzed by using the 
photoaffinity probe of aplyronines as described in the next section. 
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Figure 2-11. Structure of Arp2/3 complex (PDB code: 3DXM).  
 
Actin-ApA complex (1WUA)                       Arp3 (3DXM) 
Figure 2-12. Comparison of the structures of actin and Arp3.  
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2.3.3. Photoaffinity labeling experiments in cell lysate with ApA-PB and ApC-PB. 
The author investigated the target proteins of ApA in whole cell lysate through the reaction with 
photoaffinity probes followed by affinity purification (Figure 2-13). NeutrAvidin agarose was pretreated with 
an excess amount of ApA-PB (11) or ApC-PB (12), on which the lysate of HeLa S3 cells was loaded. After 
incubation for 2 h, photoreaction was carried out. The proteins were eluted by boiling in SDS buffer and 
detected with silver stain (Figure 2-14). 
 
Figure 2-13. Outline of photoaffinity labeling experiments in this section. 
 
Three strong bands corresponding to actin, Arp2, and Arp3 (43, 40, and 47 kDa, respectively) were 
detected with silver stain and were identified by immunoblotting analysis with anti-Arp2 and Arp3 (Figure 
2-14, a and b, lane 1). Binding of these three proteins with ApA-PB (11) were competitively inhibited by 
excess ApA (lane 2). These results suggested that there are specific interactions between the ApA analogs 
and actin or actin-related proteins, rather than their simple absorptions on the agarose resin.  
To confirm the properties of binding between ApA and its target proteins, photoreacted products were 
detected by HRP conjugate streptavidin. As expected, a strong band corresponding to actin was observed 
upon treatment with ApA-PB (11) (Figure 2-15, lane 1), and the band disappeared with the addition of excess 
ApA (lane 2). In contrast, neither Arp2 nor Arp3 was detected as a biotinylated protein. Thus, actin surely 
formed a covalent bond with ApA-PB, while actin-related proteins did not. 
When the photolabeled products were competitively eluted with ApA, both Arp2 and Arp3 were liberated 
from the resin with a quantity of actin (Figure 2-16. lane 1), while the actin covalently bound to ApA 
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derivatives was eluted only after the boiling process (lane 1’). These results indicated that Arp2 and Arp3 
might indirectly bind to ApA as the ternary adducts of the actin-ApA complex or through the oligomeric 
actin that interacts with ApA derivatives.  
Furthermore, through affinity purification with ApC-PB (12), both Arp2 and Arp3 were obtained with 
actin from cell lysate, as with ApA-PB (11), in which only the actin was photolabeled (Figure 2-14–2-16, 
lane 3). ApC (2), which lacks the C7 trimethylserine ester moiety, exhibits 1000-fold less cytotoxicity, but as 
much actin-depolymerizing activity as ApA (1) as described chapter 1. Because the much less cytotoxic 
ApC-PB (12) bound to Arp2 and Arp3 in same extent as more highly cytotoxic ApA-PB (11), actin-related 
proteins were found not to be critical target proteins of ApA (1) for its potent antitumor activity.  
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Figure 2-14. Pull-down assay using aplyronine photoaffinity probes. After photoreaction in cell lysate, 
labeled proteins were eluted from resin by boiling. The proteins were detected a) with silver stain, b) by 
immunoblotting analysis with anti-Arp2 and anti-Arp3.  
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.  
Figure 2-15. Detection of labeled proteins with aplyronine photoaffinity probes. Labeled proteins with 
ApA-PB (11) or ApC-PB (12) were detected by immunoblotting analysis with HRP conjugate streptavidin. 
 
 
 
 
 
Figure 2-16. Stepwise elution. Binding proteins on the resin were eluted by treatment with ApA (10 μM, 
lanes 1–4) followed by boiling in SDS buffer (lanes 1’–4’) and detected with a) silver stain or b) anti-Arp2 
and anti-Arp3.  
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2.4. Purification and identification of the target proteins photolabeled 
in living cells 
The target proteins which are important for the potent antitumor activity of ApA (1), were not detected by the 
pull-down assay in cell lysate. One of the possible reasons was the lack of interaction of target proteins with 
ApA-PB (11) due to the denaturation of target proteins upon the lysis and extraction steps. Therefore, 
photolabeling experiments of target proteins with ApA-PB (11) were conducted in living cells. 
 
2.4.1. Photolabeling experiments of target proteins in living cells by ApA-PB 
0.6 M of ApA-PB (11) was incubated with living HeLa S3 cells. After the incubation for 1–48 h, 
photoreaction was carried out. The whole cellular proteins were extracted and the labeled proteins were 
detected by Western blotting (WB) analysis with HRP conjugate streptavidin (Figure 2-17). When incubation 
time was 48 h, no specific biotinylated proteins were detected (Figure 2-18. lane 1), suggesting that ApA-PB 
(11) caused significant damage in HeLa S3 cells. In contrast, when incubation time was reduced to 1–24 h, 
two bands with molecular masses of 55 and 58 kDa were slightly detected along with actin (43 kDa) (lanes 
2–4). Since these three proteins were not detected without ApA-PB (11) (lane 5), these proteins were labeled 
by ApA-PB (11). Amount of the labeled actin were slightly increased as incubation time increased from 1 to 
24 h. However the labeling efficiency of 55 and 58 kDa proteins was not changed by the incubation time.  
 
 
Figure 2-17. Outline of in situ photolabeling experiments. 
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Figure 2-18. In situ photolabeling experiments with various incubation times. 0.6 M of ApA-PB (11) was 
added to HeLa S3 cells. After incubation for 1, 3, 24 or 48 h, photoreaction was carried out. Labeled proteins 
were detected by Western blotting analysis with HRP conjugate streptavidin. 
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To improve the labeling efficiency of additional target proteins, WB condition was optimized. First the 
blocking condition was changed from 5% to 0.5% skim-milk in PBS-T to prevent over-blocking. Then dosed 
amount of ApA-PB (11) were examined (Figure 2-19). The labeled amount of the actin (43 kDa) and 
additional target proteins (55 and 58 kDa) were increased as in a dose-dependent manner. When cells 
were treated with 5 M ApA-PB (11), two additional bands were also detected in 50 and 60 kDa (lane 4).  
 
 
 
 
 
Figure 2-19. Dose-dependence on in situ photolabeling experiments. 0, 1, 2.5 or 5 M of ApA-PB (11) were 
added to HeLa S3 cells. After photoreaction, labeled proteins were detected by WB analysis with HRP 
conjugate streptavidin. Arrowheads indicate 55 kDa and 58 kDa proteins.  
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To confirm whether detected proteins were specifically labeled with ApA-PB (11), competitive experiments 
with excess ApA (1) were conducted (Figure 2-20). ApA (1) inhibited the labeling of not only actin but also 
the 55 and 58 kDa proteins (lane 1), suggesting their specific interaction with ApA (1). On the other hand, 
other biotinylated proteins with the molecular weight of 50 and 60 kDa were still detected in the presence of 
excess actin (lane 2). Therefore these two proteins were found to be non-specific binding proteins, which did 
not specifically interact with natural ApA (1). 
 
 
 
Figure 2-20. In situ photolabeling experiments in the absence/presence of excess ApA (1). The arrows show 
the 55 kDa and 58 kDa proteins which bound specifically to ApA-PB (11). Asterisks indicate the 50 kDa and 
60 kDa proteins that non-specifically bound to ApA-PB (11). 
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2.4.2. Purification and identification of proteins photlabeled with ApA-PB. 
In the section 2.4.1. the photolabeled proteins in the whole cell lysate were detected without affinity 
purification. To identify the two 55 and 58 kDa proteins, affinity purification of the photolabeled proteins 
was conducted (Figure 2-21). After photoreaction with ApA-PB (11) in living cells, the whole cellular 
proteins were extracted. The labeled proteins were purified with the use of NeutrAvidin agarose, and detected 
with silver stain and HRP conjugate streptavidin (Figure 2-22). A lot of proteins were nonspecifically 
absorbed to the resin, and affinity purified proteins that specifically purified by ApA-PB (11) except actin 
were hard to be detected by silver staining (lane 1). Meanwhile 55 and 58 kDa proteins were clearly detected 
with HRP conjugate streptavidin, and labeling of these proteins were inhibited in the presence of excess ApA 
(1) (lane 3). When ApC-PB (12) was used in the same experiments, 55 and 58 kDa were not labeled, and yet 
actin was labeled as with ApA-PB (11) (lane 2). These results indicate that 55 and 58 kDa proteins 
specifically bound to ApA (1), and were critical target proteins of ApA (1) for its potent antitumor activity. 
 
 
Figure 2-21. Outline of in situ photolabeling experiment and purification of labeled proteins.  
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Figure 2-22. Affinity purification of the photoreacted proteins. After photoreaction with ApA-PB (11) or 
ApC-PB (12) in situ, labeled proteins were purified with NeutrAvidin resin. Purified proteins were detected 
with a) silver stain or b) HRP conjugate streptavidin. Arrowhead indicate the 55 and 58 kDa bands. 
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2.4.3. PMF analysis 
It was confirmed that the photolabeled proteins were contained in the 55 kDa and 58 kDa bands after affinity 
purification. The author used PMF analysis for identification of major components in these two bands. Two 
bands of 55 kDa and 58 kDa were excised from the gel. After trypsin digestion, mass spectra of generated 
peptides were analyzed (Figures 2-23 and 2-24). The list of peptide masses were transferred into the peptide 
mass fingerprint search program MS-Fit. The observed masses of five peptides (K1-K5) and twelve peptides 
(K1-K12) were matched to the theoretical values based on the amino acid sequence of -tubulin and 
-tubulin (Tables 2-3 and 2-4, figures 2-25 and 2-26) Thus, it was determined that β-tubulin and α-tubulin 
were major components in the 55 kDa protein and β-tubulin was major component in the 58 kDa protein, 
respectively. 
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Figure 2-23. MALDI-TOF MS analysis of the tryptic peptides derived from the 55 kDa protein. Red check 
marks represent peptide ions that correspond to human α-tubulin; Blue check marks represent peptide ions 
that correspond to human β-tubulin. “x” represent the peptides derived from actin and non-specific 
contaminants (trypsin, keratin, etc) 
Table 2-3. Tryptic peptides of the 55 kDa protein observed by the MALDI-TOF MS analysis.  
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Figure 2-24. MALDI-TOF MS analysis of the tryptic peptides derived from the 58 kDa protein. Blue check 
marks represent peptide ions that correspond to human β-tubulin. “x” represent the peptides derived from 
actin and non-specific contaminants (trypsin, keratin, etc) 
 
Table 2-4. Tryptic peptides of the 58 kDa protein observed by the MALDI-TOF MS analysis. 
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Figure 2-25. Amino acid sequence of human α-tubulin. The sequences of the tryptic fragments (K1-K5) 
identical to the MS data are shown as solid underlines. 
 
 
 
 
 
Figure 2-26. Amino acid sequence of human β-tubulin. The sequences of the tryptic fragments (K1-K12) 
identical to the MS data are shown as solid underlines. 
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2.4.4. Immunoblotting analysis 
To confirm that the photolabeled proteins (55 kDa and 58 kDa) were tubulin, immunoblotting analysis with 
anti-tubulin antibody were carried out. After in situ photoreaction and affinity purification, -tubulins were 
detected by immunoblotting analysis (Figure 2-27). Native -tubulins in HeLa S3 cells were detected in 55 
kDa. As shown in lane 4, a certain amount of -tubulin was non-specifically absorbed to the resin. However 
by using ApA-PB (11), amount of purified -tubulin was markedly increased and the 58 kDa band was 
detected (lane 1). By competition of excess ApA (1), the amount of 55 kDa -tubulin reduced to almost the 
same level as control, and the 58 kDa band was disappeared (lane 3). Therefore it was suggested that the 58 
kDa was the -tubulin which was covalently bound to ApA-PB (11). These results indicated that -tubulin 
specifically interact with ApA (1). Furthermore by using ApC-PB (12), the amount of -tubulin was not as 
much as with ApA-PB (11) (lane 2), as with the detection with HRP conjugate streptavidin (Figure 2-22, lane 
2).  
In the same immunoblotting analysis were performed with anti--tubulin (Figure 2-28). Native 
-tubulins in HeLa S3 cells were detected in 53 kDa. Contrary to expectations, the amount of -tubulin was 
the same level as control in the both case of ApA-PB (11) or ApC-PB (12) (lanes 1 and 2). No additional 
bands with the higher molecular weight were observed. Therefore direct interaction between -tubulin and 
ApA has not been established based on these studies.  
 
 
 
 
 
 
 
 
57 
 
 
 
 
 
 
 
 
 
Figure 2-27. Immunoblotting analysis with anti--tubulin of purified proteins labeled in situ.  
 
 
 
 
 
Figure 2-28. Immunoblotting analysis with anti--tubulin of purified proteins labeled in situ. 
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2.5. Conclusion 
ApA-bio (7) that has biotin group and ApA-PB (11) that has biotin and photoaffinity groups were 
synthesized. They maintained the potent cytotoxicity and actin-depolymerizing activity of ApA (1).  
By using the ApA-bio (7), Arp2 and Arp3 were specifically purified as binding proteins along with actin 
from tumor cell lysate. Additionally with the use of ApA-PB (11), Arp2 and Arp3 were also specifically 
purified from tumor cell lysate. However, ApA-PB (11) did not covalently bind to Arp2 and Arp3. Thus, 
actin-related proteins might indirectly bind to ApA (1) as the ternary adducts of the actin-ApA complex or 
through the oligomeric actin. With the use of ApC-PB (12), Arp2 and Arp3 were also purified as with 
ApA-PB (11), therefore Arp2 and Arp3 were not important proteins for potent cytotoxicity of ApA (1). 
After photoreaction with ApA-PB (11) in living cells, two labeled proteins were detected along with actin 
and identified as - and -tubulin. Since the labeling of tubulin was inhibited by competition of excess ApA 
(1) along with actin, tubulin might specifically interact with ApA (1). Furthermore ApC-PB (12) did not 
interact with tubulin. It is suggested that tubulin is a critical target protein of ApA (1) for its potent antitumor 
activity.  
 
 
  
59 
 
2.6. Experimental  
The synthesis of ApA-biocytin (6) and ApA-bio (7), and PMF analysis of Arp2 and Arp3 were performed by 
co-workers. 
 
2.6.1. General 
Chemicals and solvents were the best grade available and were used as received from commercial sources. 
To protect aryl diazirine derivatives from the light, all synthetic and biological experiments with aryl 
diazirine derivatives were conducted with light-shaded glass or plastic equipment, or under a yellow-filtered 
light hood. For bioassays, the experiments that used cell lysate and proteins were performed on ice unless 
otherwise noted. The protein concentration was measured with a Bio-Rad Protein Assay Kit (Bradford’s 
method) with BSA as a standard. 
TLC analysis was conducted on E. Merck precoated silica gel 60 F254 (0.25 mm layer thickness), HPTLC 
Silica gel 60 RP-18 WF254s, or HPTLC Silica gel 60F254. Fuji Silysia silica gels BW-820 MH and FL-60D, 
Merck Aluminum oxide 90 standardized, and Nacalai tesque COSMOSIL 75C18-OPN were used for open 
column chromatography. NMR spectra were recorded on a Bruker Biospin AVANCE 600 spectrometer (600 
MHz for 
1
H and 150 MHz for 
13
C), a Bruker Biospin AVANCE 400 spectrometer (400 MHz for 
1
H and 100 
MHz for 
13
C) or a JEOL JNM-EX270 spectrometer (270 MHz for 
1
H). Chemical shifts are reported in parts 
per million (ppm) with coupling constants (J) in hertz relative to the solvent peaks, δH 3.30 (residual 
CHD2OD) and δC 49.0 for CD3OD, δH 7.26 (residual chloroform) and δC 77.0 for (CDCl3), or δH 2.50 
(residual CHD2S(O)CD3) and δC 39.5 for [(CD3)2S= O], respectively. For the quantification of minute 
amounts of samples by 
1
H NMR analyses, 1,4-dioxane, dichloromethane or benzene (10 mM in CD3OD) was 
added to the sample solutions as a standard (1:60 v/v). Optical rotations were measured with a JASCO 
DIP-1000 polarimeter. IR spectra were recorded on a JASCO FT/IR-230 spectrometer. High-resolution 
electrospray ionization mass spectra (HR-ESIMS) were measured on a QSTAR Pulsar i spectrometer 
(Applied Biosystems) or an AccuTOF CS spectrometer (JEOL). Matrix-assisted laser desorption/ionization 
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with time-of-flight mass spectrometry (MALDI-TOF MS) was performed using a Bruker ultrafleXtreme 
spectrometer with α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix.  
  
2.6.2. Cell culture and cytotoxicity assay.  
HeLa S3 cells (suspension culture-adapted human cervical carcinoma cell line, ATCC CCL-2.2) were 
cultured in Eagle’s minimal essential medium (E-MEM) supplemented with fetal bovine serum (FBS, 10%) 
in a humidified atmosphere containing CO2 (5%) at 37 °C. The cytotoxicities of ApA and its derivatives were 
measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. HeLa S3 
cells were seeded at 2 × 10
3
 cells per well in 96-well plates. After incubation overnight at 37 °C, aplyronines 
and these derivatives (1 pM – 1 µM) were added, and the cells were incubated for 96 h at 37 °C. After MTT 
was added, the mixtures were incubated for 4 to give insoluble formazan derivative from MTT. After removal 
of the medium, the formazan derivative was dissolved with N,N-dimethylformamide and absorbance at 540 nm 
was measured on Infinite F200 PRO (TECAN). The IC50 value (concentration required for 50% inhibition of 
cell growth) was determined using a growth curve by comparison of negative control wells. 
 
2.6.3. In vitro actin-depolymerizing assay.  
The actin-depolymerizing activities of ApA (1) and model compounds were measured based on their ability 
to attenuate the fluorescence of pyrene-conjugated (pyrenyl) actin. Actin polymerization was started by the 
addition of a 0.15 M solution of MgCl2 (3.3 µL) to a solution of actin (3 µM, from rabbit skeletal muscle, 
Cytoskeleton Inc., 10% of total actin is pyrenyl-actin) in 500 µL of G-buffer [2 mM Tris·HCl (pH8.0), 0.2 
mM CaCl2, 0.2 mM ATP, 0.5 mM 2-mercaptoethanol]. After incubation for 1 h at 25 °C, ApA (1) and its 
derivatives were added, and the time course of polymerization (or depolymerization) was continuously 
monitored by measuring fluorescence of pyrenyl-actin with spectrofluorometer (Hitachi, F-4500, equipped 
with a magnetic stirrer) at 25 °C at 365nm excitation and 407nm emission wavelengths. 
In another assay of F-actin sedimentation (centrifugation method), to a solution of actin (3 µM, from 
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rabbit skeletal muscle, Cytoskeleton) in G-buffer (500 µL) was added a 0.15 M solution of MgCl2 (3.3 µL), 
and the mixture was stirred at 25 °C for 1 h. To the solutions of F-actin were added samples (3 µM), and the 
resulting mixtures were stirred at 25 °C for 1 h and then ultracentrifuged (150,000 × g, 22 °C, 1 h). The 
supernatants (lyophilized) and the precipitates were dissolved in 1 × SDS buffer (100 µL, Sigma) and boiled 
at 95 °C for 5 min. SDS-PAGE was performed by using a precast 10% polyacrylamide gel (ATTO), and the 
gels were stained with a Quick-CBB kit (Wako).  
 
2.6.4. Interaction of biotinylated ApA derivatives with actin.  
1 mM solutions of samples (5 µL) were pre-incubated with the NeutrAvidin agarose resin (10 µL, Pierce) 
equilibrated with G-buffer (250 µL) with a rotator at 4 °C for 2 h. After the unbound samples were removed 
by decantation, actin (50 µg/mL, from rabbit muscle, Sigma Co.) in G-buffer (240 µL) was added to the resin, 
and the mixtures were incubated with a rotator at 4 °C for 23 h. The resins were thoroughly washed with 
0.1% Triton PBS (4 × 400 µL) followed by PBS (400 µL). In the case of elution by ApA (1), the resins were 
incubated with ApA (1) (5 µM) in G-buffer (40 µL) with a rotator at room temperature for 2 h, and the 
supernatants were collected by filtration. The elutes were diluted with an equal volume of 2 × SDS buffer 
(Sigma Co.) and boiled at 95 °C for 5 min. In the case of elution by boiling, the resins were resuspended in 2 
× SDS buffer (30 µL) and boiled at 95 °C for 5 min. SDS-PAGE was performed by using a precast 10% 
polyacrylamide gel (ATTO Co.), and the gels were stained with a Silver Stain Kit, Protein (GE Healthcare).  
 
2.6.5. Pull-down assay of the ApA-binding proteins in cell lysate.  
1 mM solutions of samples (5 µL) were pre-incubated with NeutrAvidin agarose resin (10 µL) equilibrated 
with 0.1% Triton PBS (250 µL) with a rotator at 4 °C for 2 h. After unbound samples were removed by 
decantation, the cell lysate (277 µL, 3 mg protein, from 2 × 10
7
 cells) was added to the resin and incubated 
with a rotator at 4 °C for 15 h. The resins were thoroughly washed with 0.1% Triton PBS (4 × 400 µL) 
followed by PBS (400 µL). Binding proteins were eluted by the ApA (1) or boiling as described in 2.6.4. 
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except for the use of 0.1% Triton-PBS instead of G-buffer. SDS-PAGE was performed by using a precast 
10% polyacrylamide gel (ATTO Co.), and the gels were stained with a Silver Stain Kit, Protein (GE 
Healthcare). For the immunoblot analyses, proteins in the gels after electrophoresis were transferred to 
PVDF membranes using the Trans-Blot
®
 SD semi-dry blotting system (Bio-Rad) according to the 
manufacturer’s instructions. After transfection, PVDF membranes were blocked with 5% skim-milk in PBS. 
Proteins were detected with HRP conjugated streptavidin (1:2000, GE Healthcare), rabbit polyclonal 
anti-nonmuscle myosin IIB antibody (1:200, GeneTex Inc., cat. No. GTX11090), rabbit polyclonal 
anti-β-actin antibody (1:200, Sigma Co., cat. No. A2066), rabbit polyclonal anti-Arp2 antibody (1:200, CST 
Japan, cat. No. #3128S), rabbit polyclonal anti-Arp3 antibody (1:200, CST Japan, cat. No. #4738S), or 
mouse monoclonal anti-ACTR3 (actin-related protein 3 homolog) antibody (1:200, 2B6, Abnova Co., cat. 
No. H00010096-M02). For the all primary antibodies, proteins were further treated with HRP-conjugated 
anti-rabbit or anti-mouse IgG (1:2000, GE Healthcare). HRP-conjugated bands were visualized with an ECL 
or ECL-prime systems (GE Healthcare), and detected by a Fujifilm LAS-4000 MINI imaging scanner.  
 
2.6.6. Photolabeling and affinity purification of aplyronine binding proteins in HeLa 
S3 cell lysate.  
HeLa S3 cells (4.0 × 10
7
 cells) in culture were washed twice with PBS and treated with 0.05% trypsin–
EDTA. Suspended cells were collected by centrifugation and washed twice with PBS. The cells were lysed in 
1 mL of lysis buffer [10 mM Tris·HCl (pH 7.4), 0.15 M NaCl, 1% Triton X-100, 10 mg/mL leupeptin] with a 
pestle at 4 °C. To remove most of the intrinsic biotin-binding proteins, the suspensions were centrifuged 
(15,000 rpm, 30 min) and treated with NeutrAvidin agarose resin (200 µL, Pierce) equilibrated with 0.1% 
Tween 20 in PBS (PBS-T) with a rotator for 30 min. The supernatants were collected by filtration to give the 
cell lysate (~1.3 mL) with a concentration of 10 mg protein/mL. Solution of ApA-PB or ApC-PB in dimethyl 
sulfoxide (1 mM, 5 µL) and lysis buffer (50 µL) was added to the NeutrAvidin agarose resin (40 µL) in 1.5 
mL Eppendorf tubes. After the incubation with a rotator shielded from light for 30 min, the cell lysate (300 
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µL) was added, and the mixtures were further incubated for 2 h. For competitive inhibition assays, a 10 mM 
solution of ApA in dimethyl sulfoxide (5 µL) was pretreated with the cell lysate for 30 min. Then the 
resulting mixture was irradiated with UV lamp 0.8 mW/cm
2
 on ice for 15 min. For the direct elution by 
boiling, the resins divided in half were thoroughly washed with PBS-T (5 × 400 µL) followed by PBS (400 
µL) and resuspended in 2 × SDS buffer (30 µL). The binding proteins were eluted by boiling at 95 °C for 5 
min. For the stepwise elution, the remaining half of the resins washed with PBS-T (5 × 400 µL) were 
incubated with ApA (1) (10 µM) in PBS-T (100 µL) with a rotator at room temperature for 2 h, and the 
supernatants were collected by filtration. The eluates were lyophilized, dissolved in 2 × SDS buffer (30 µL, 
Sigma Co.), and boiled at 95 °C for 5 min. The residual resins were resuspended in 2 × SDS buffer (30 µL), 
and binding proteins were eluted by boiling at 95 °C for 5 min. SDS-PAGE was performed by using a precast 
10% polyacrylamide gel, and the gels were stained with a Silver Stain Kit, Protein. Immunoblotting analyses 
were performed as described in 2.6.5. Proteins were detected with HRP-conjugated streptavidin (1:3000, GE 
Healthcare), rabbit polyclonal anti-Arp2 antibody (1:200, CST Japan, cat. No. #3128S), or rabbit polyclonal 
anti-Arp3 antibody (1:200, CST Japan, cat. No. #4738S). For the both primary antibodies, proteins were 
further treated with HRP-conjugated anti-rabbit IgG (1:2000, GE Healthcare). The HRP-conjugated bands 
were visualized with an ECL-prime system (GE Healthcare), and detected by a Fujifilm LAS-4000 MINI 
imaging scanner.   
 
2.6.7. In-gel digestion and PMF analysis. 
After SDS-PAGE, gels were silver-stained in a mass-compatible manner
10
 (Silver staining was performed 
except that treatment with glutaraldehyde, a cross-linking and sensitizing agent). The gel was fixed in 50% 
methanol, 5% acetic acid in water for 30 min. After washing with H2O, the gel was sensitized for 2 min in 
0.02% sodium thiosulfate and then rinsed with H2O (2 × 1 min). The gel was treated with 0.25% silver 
nitrate solution for 30 min. After the silver nitrate solution was discarded, the gel was rinsed twice with water 
for 1 min and then developed in 0.004% formalin in 2% sodium carbonate for 1 min. The development was 
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terminated by discarding the reagent, followed by washing of the gel with 1% acetic acid. Stained spots were 
excised from the PAGE gel, and the gel pieces were desilverized by vortexing in 30 mM potassium 
ferricyanide / 100 mM sodium thiosulfate (1:1) for 10 min, followed by washing with H2O twice. H2O was 
replaced with acetonitrile to dehydrate the gel pieces. After removal of liquid phase, they were completely 
dried in a centrifugal evaporator. A volume of 10 mM dithiotreitol (DTT) in 25 mM ammonium bicarbonate 
sufficient to cover the gel pieces was added, and the DTT solution was incubated for 45 min at 56 °C. The 
DTT solution was replaced with roughly the same volume of 55 mM iodoacetamide in 100 mM ammonium 
bicarbonate. After vortexing in the dark for 30 min, the gel pieces were washed with 25 mM ammonium 
bicarbonate for 5 min. Washed gel pieces were incubated in acetonitrile–25 mM ammonium bicarbonate 
(1:1), and dehydrated by replace washed solvent with acetonitrile. The liquid phase was removed, and the gel 
pieces were completely dried in a centrifugal evaporator. The gel pieces were incubated with the modified 
trypsin (1:100 w/w, sequence-grade, #V5111, Promega) in 25 mM ammonium bicarbonate for 19 h at 37 °C.
 
The tryptic peptide mixtures were extracted from the gel pieces with 5% formic acid50% acetonitrile (three 
times). All extracts were combined and concentrated to the 10 µL in a centrifugal evaporator. The solution 
was desalted by using a prespotted Anchorchip™ (PAC 384/96 α-CHCA, Bruker Daltonics), according to the 
manufacturer’s instruction for MS and MS/MS analyses. PMF searches to identify proteins were performed 
using MS-fit in ProteinProspector (http://prospector.ucsf.edu/prospector/mshome.htm). Database was 
SwissProt. Partial methionine oxidation, N-terminal acetylation and pyro-glutamate, complete cysteine 
carbamidomethylation, and one or no missed trypsin cleavages were factors considered in the searches. 
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2.6.8. Isolation of aplyronine A (1) 
Aplyronine A (1) was isolated from the sea hare Aplysia kurodai. The specimens of sea hare were collected 
off the Pacific coast of the Shima Peninsula, Mie Prefecture, Japan. Approximately 16 kg (wet weight) of sea 
hare was crashed and extracted with ethanol (30 L) for 2 days. The extracted was filtered, and the filtrate was 
concentrated. The residue was partitioned between ethyl acetate (3 × 1 L) and water (1 L). The ethyl acetate 
layer was concentrated, and the residue was partitioned between 90% methanol (1 L) and hexane (4 × 0.5 L). 
The 90% methanol layer was concentrated, and the residue was partitioned between 60% methanol (1 L) and 
dichloromethane (6 × 0.5 L). The dichloromethane layer was concentrated. The residue (17.8 g) was loaded 
on a silica gel column (300 g) and eluted with benzene–ethyl acetate–methanol (1:1:0 → 0:1:0 → 0:4:1 → 
0:1:1 → 0:0:1). The concentrated fraction (1.25 g) eluted with benzene–ethyl acetate–methanol 0:1:1 was 
loaded on aluminum oxide column (35 g) and eluted with ethyl acetate–methanol (1:0→19:1→1:1). The 
concentrated fraction (34.4 mg) eluted with ethyl acetate–methanol (19:1) was chromatographed by 
reversed-phase HPLC [Develosil ODS-HG-5 (20 mm I.D. × 250 mm), methanol–0.01 M ammonium 
acetate (70:30), 5 mL/min] and column chromatography on aluminum oxide [0.5 g, ethyl acetate–methanol 
(1:1)] to give aplyronine A (1) (5.1 mg, 3.2×10
-5
% based on wet wt). 
 
 
 
  
66 
 
2.6.9. Synthesis and spectroscopic data of aplyronine derivatives and model 
compounds.  
ApA-biocytin (6). *                                  *The experiments performed by co-workers. 
 
 
 
To a stirred solution of ApA (1) (0.50 mg, 460 nmol) in acetonitrile (0.1 mL) was added 1 M aq. HCl (0.1 
mL) under a nitrogen atmosphere. After being stirred for 26 h at room temperature, the reaction mixture was 
diluted with ethyl acetate (5 mL), washed with water and brine, dried, and concentrated to give aldehyde 8, 
which was used for the next step without further purification. The crude material was dissolved in 50% aq. 
methanol (0.5 mL), and biocytin (2.0 mg, 5.3 µmol, Nakalai Tesque) was added under a nitrogen atmosphere. 
After the mixture was stirred for 30 min, sodium cyanoborohydride (1.2 mg, 18 µmol) was added. The 
mixture was stirred for an additional 36 h and concentrated. The residue was applied (twice) to a Develosil 
300C4-HG-5 reversed-phase HPLC column ( 4.6 mm I.D. × 250 mm). Samples were eluted by acetonitrile–
20 mM ammonium acetate (4:6) at a flow rate of 0.5 mL/min, with monitoring at 220 nm, to give a 
ApA-biocytin (6) (157 µg, 24%, based on NMR quantification, tR = 15.1 min). Compound 6: 
1
H NMR (600 
MHz, CD3OD) δ 7.21 (dd, J = 15.4, 10.5 Hz, 1H), 6.39 (br dd, J = 15.2, 10.5 Hz, 1H), 6.23 (m, 1H), 5.98 (d, 
J = 15.4 Hz, 1H), 5.64 (ddd, J = 15.4, 10.9, 3.6 Hz, 1H), 5.56 (br d, J = 10.8 Hz, 1H), 5.10 (m, 1H), 4.94–
4.58 (m, 5H), 4.48 (m, 1H), 4.30 (m, 1H), 3.67 (m, 2H), 3.59–3.50 (m, 2H), 3.45–3.07 (m, 6H), 3.36 [3.41] 
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(s, 3H), 3.18 (s, 3H), 3.16 (s, 3H), 2.92 (br dd, J = 13.0, 4.9 Hz, 1H), 2.88 (m, 1H), 2.70 (br d, J = 13.0 Hz, 
1H), 2.52–2.38 (m, 2H), 2.39 (s, 3H), 2.38 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H), 2.28 (br d, J = 14.0 Hz, 1H), 
2.19 (br t, J = 7.1 Hz, 2H), 2.10–1.95 (m, 6H), 2.04 [2.03] (s, 3H), 1.94–1.77 (m, 6H), 1.76–1.50 (m, 12H), 
1.52 [1.51] (br s, 3H), 1.47–1.38 (m, 4H), 1.36–1.22 (m, 4H), 1.30 [1.29] (d, J = 7.2 Hz, 3H), 1.18–1.08 (m, 
4H), 1.03 (d, J = 7.2 Hz, 3H), 1.01 (d, J = 7.3 Hz, 3H), 1.00 (d, J = 6.9 Hz, 3H), 0.98 (d, J = 7.3 Hz, 3H), 
0.97 (d, J = 6.9 Hz, 3H), 0.92 (br d, J = 7.0 Hz, 3H), 0.77 [0.78] (d, J = 6.1 Hz, 3H). Chemical shifts of the 
minor diastereomer are within brackets. HRMS (ESI) m/z 696.4544 (calcd for C73H128N6O17S)/2 [M+2H]
2+
 , 
Δ +1.4 mmu).  
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ApA-bio (7) *                                       *The experiments performed by co-workers. 
 
 
 
To a stirred solution of ApA (1.0 mg, 930 nmol) in 1,4-dioxane (0.3 mL) was added 2 M aq. HCl (0.1 mL) 
under a nitrogen atmosphere. After being stirred for 80 min at 50 °C, the reaction mixture was neutralized 
with sodium bicarbonate (3 mL) and extracted with chloroform (2 mL × 4). The combined extracts were 
washed with brine and concentrated to give aldehyde 8, which was used for the next step without further 
purification. To the stirred solution of aldehyde 8 in methanol–acetic acid (4:1, 0.4 mL) was added EZ-Link 
Biotin-PEG4-Hydrazide (2.5 mg, 5 µmol, Thermo Scientific) in dimethyl sulfoxide (20 µL) under a nitrogen 
atmosphere. After the mixture was stirred for 48 h at room temperature, acetone (50 µL) was added. After 
additional stirring for 30 min, the reaction mixture was azeotropically concentrated with toluene and applied 
(five times) to a Develosil ODS-HG-5 reversed-phase HPLC column ( 4.6 mm I.D. × 250 mm). Samples 
were eluted by methanol–40 mM ammonium acetate (73:27) at a flow rate of 1 mL/min, with monitoring at 
254 nm, and then lyophilized from water twice to give ApA-bio (7) (540 µg, 38%, based on NMR 
quantification, tR = 25.3 min, E/Z = 2/1 for the C34 isomers). Compound 7: 
1
H NMR (600 MHz, CD3OD) δ 
7.48 [7.30] (t, J = 5.7 Hz, 1H), 7.20 (dd, J = 15.1, 10.7 Hz, 1H), 6.38 (br dd, J = 15.3, 10.7 Hz, 1H), 6.22 (m, 
1H), 5.97 (d, J = 15.1 Hz, 1H), 5.64 (ddd, J = 15.4, 10.9, 3.6 Hz, 1H), 5.55 (br d, J = 10.7 Hz, 1H), 5.10 (m, 
1H), 4.97 (m, 1H), 4.95–4.78 (m, 2H), 4.68 (m, 1H), 4.48 (dd, J = 7.8, 5.0 Hz, 1H), 4.30 (dd, J = 7.8, 4.6 Hz, 
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1H), 3.77 [3.79] (t, J = 6.0 Hz, 2H), 3.68 (t, J = 5.9 Hz, 2H), 3.67 (t, J = 5.8 Hz, 2H), 3.66–3.58 (m, 12 H), 
3.55 (m, 1 H), 3.53 (t, J = 6.0 Hz, 2H), 3.52 (m, 1 H), 3.37–3.14 (m, 5H), 3.34 [3.41] (s, 3H), 3.18 (s, 3H), 
3.16 (s, 3H), 3.08 (m, 1H), 2.92 (br dd, J = 12.8, 5.0 Hz, 1H), 2.88 (m, 1H), 2.70 (br d, J = 12.8 Hz, 1H), 
2.52–2.35 (m, 3H), 2.47 (t, J = 6.0 Hz, 1H), 2.39 (s, 3H), 2.38 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H), 2.28 (br d, 
J = 14.0 Hz, 1H), 2.22 (br t, J = 7.3 Hz, 2H), 2.11–1.90 (m, 4H), 2.04 [2.03] (s, 3H), 1.76–1.49 (m, 13H), 
1.51 [1.52] (br s, 3H), 1,43 (m, 2H), 1.39–1.23 (m, 4H), 1.31 [1.29] (d, J = 7.1 Hz, 3H), 1.18–1.07 (m, 2H), 
1.03 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 7.3 Hz, 3H), 0.92 
[0.91] (d, J = 6.8 Hz, 3H), 0.90 [0.89] (d, J = 7.1 Hz, 3H), 0.77 [0.76] (d, J = 6.0 Hz, 3H). Chemical shifts 
of the minor hydrazone stereoisomer are within brackets. HRMS (ESI) m/z 761.9811 (calcd for 
C78H137N7O20S)/2 [M+2H]
2+
 , Δ –0.9 mmu).  
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Model-bio 10.*                                      *The experiments performed by co-workers. 
 
 
 
To a stirred solution of 3-phenylpropionaldehyde (3.4 mg, 25 µmol) in methanol–acetic acid (4:1, 2 mL) was 
added EZ-Link Biotin-PEG4-Hydrazide (12.6 mg, 25 µmol) in dimethyl sulfoxide (100 µL) under a nitrogen 
atmosphere. After being stirred for 24 h at 50 °C, the reaction mixture was concentrated and applied (twice) 
to a Develosil ODS-HG-5 HPLC column ( 20 mm I.D. × 250 mm). Samples were eluted by 80% aqueous 
methanol at a flow rate of 5 mL/min, with monitoring at 215 nm (tR = 12.5 min) to give Model-bio 10 (5.9 
mg, 38%, E/Z = 2/1 for the imine carbonyl carbon). Compound 10: 
1
H NMR (600 MHz, CD3OD) δ 7.47 
[7.31] (t, J = 5.5 Hz, 1H), 7.26 (br t, J = 7.6 Hz, 2H), 7.22 (br d, J = 7.6 Hz, 2H), 7.16 (br t, J = 7.6 Hz, 1H), 
4.47 (ddd, J = 7.8, 5.0, 0.7 Hz, 1H), 4.09 (dd, J = 7.8, 4.6 Hz, 1H), 3.75 (t, J = 6.1 Hz, 2H), 3.63–3.57 (m, 
12H), 3.52 (t, J = 5.5 Hz, 2H), 3.34 (t, J = 5.5 Hz, 2H), 3.19 (m, 1H) 2.91 (dd, J = 12.7, 5.0 Hz, 1H), 2.85 (t, 
J = 7.4 Hz, 2H), 2.69 (br d, J = 12.7 Hz, 1H), 2.60 [2.57] (dt, J = 5.5, 7.8 Hz, m, 2H), 2.45 (t, J = 6.1 Hz, 
2H), 2.20 (t, J = 7.3 Hz, 2H), 1.72 (m, 1H), 1.69–1.60 (m, 2H), 1.59 (m, 1H), 1.43 (tt, J = 7.3, 7.3 Hz, 2H). 
Chemical shifts of the minor hydrazone stereoisomer are within brackets. 
13
C NMR (150 MHz, CD3OD) δ 
176.1 (s), 170.1 (s), 166.1 (s), 153.1 [149.1] (d), 142.1 [142.5] (s), 129.5 (d, 2C), 129.1 (d, 2C), 127.2 [127.1] 
(d), 71.6 (t, 2C), 71.5 (t, 2C), 71.4 (t), 71.3 (t), 70.6 (t), 68.0 (t), 63.4 (d), 61.6 (d), 57.0 (d), 41.0 (t), 40.4 (t), 
36.7 (t), 36.3 (t), 35.0 [34.1] (t), 33.7 [33.4] (t), 29.8 (t), 29.5 (t), 26.8 (t); IR (chloroform) 3466, 3265 (br.), 
3006, 2926, 1698, 1523, 1455, 1350, 1249, 1111 cm
-1; [α]D
19
 +28 (c 0.37, methanol); HRMS (ESI) m/z 
644.3108 (calcd for C30H47N5NaO7S [M+Na]
+
 , Δ +1.7 mmu).  
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Biotin-PEO4-amine 13.
6
  
 
 
 
To a stirred solution of bis[2-(3-aminopropoxy)ethyl]ether (650 µL, 2.95 mmol) and triethylamine (70 µL, 
0.50 mmol) in N,N-dimethylformamide (1 mL) was added (+)-biotin N-hydroxysuccinimidyl ester (100.8 mg, 
0.295 mmol) in 5 mL of N,N-dimethylformamide dropwise for 45 min. After being stirred at room 
temperature for 2 h, the mixture was concentrated under vacuum and azeotropically dried with toluene twice. 
The residual oil was triturated with diethyl ether (15 mL) and stirred for 1 h. The solid was collected by 
filtration, dissolved in methanol–ethyl acetate (4:1), and loaded on aluminum oxide column (5 g). Samples 
were eluted with methanol–ethyl acetate (4:1) to give the biotin-PEO4-amine 13 (88.4 mg, 67%). Compound 
13: 
1
H NMR (270 MHz, CD3OD) δ 4.48 (dd, J = 4.1, 7.7 Hz, 1H), 4.29 (dd, J = 4.6, 7.7 Hz, 1H), 3.66–3.48 
(m, 12H), 3.25 (t, J = 7.0 Hz, 2H), 3.23–3.16 (m, 1H), 2.92 (dd, J = 4.6. 12.7 Hz, 1H), 2.75 (t, J = 6.8 Hz, 
2H), 2.69 (d, J = 12.7 Hz, 1H), 2.19 (t, J = 7.3 Hz, 2H), 1.80–1.38 (m, 10H). 
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PEG-linked biotin amide 15.  
 
 
 
To a stirred solution of carboxylic acid 14
7
 (58.3 mg, 0.130 mmol) and biotin-PEO4-amine 13 (45.4 mg, 
0.102 mmol) in dry dichloromethane (8 mL) were added 1-hydroxy-7-aza-benzotriazole (HOAt) (21 mg, 
0.16 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl) (40 mg, 
0.21 mmol). After being stirred at room temperature for 2 h, the reaction mixture was washed with sat. 
sodium hydrogen carbonate aq. (10 mL × 2), and the washings were extracted with chloroform (2 mL × 2). 
The combined organic layer and the extracts were dried with Na2SO4 and concentrated. The crude material 
was purified with an ODS column (2 g, acetonitrile) and a recycling HPLC [JAIGEL-1H, JAIGEL-2H ( 20 
mm I.D. × 300 mm), chloroform, 3.8 mL/min, UV254 nm] to give amide 15 (65 mg, 74%) as a colorless oil. 
Compound 15: [α]D
22
 +11.5 (c 0.87, chloroform); 
1
H NMR (600 MHz, CDCl3) δ 7.90–7.78 (m, 5H), 7.31–
7.26 (m, 1H), 6.78 (br s, 1H), 6.10 (br s, 1H), 5.64 (br d, J = 8.4 Hz, 1H), 5.19 (br s, 1H), 4.70 (s, 2H), 4.50 
(dd, J = 5.0, 7.7 Hz, 1H), 4.35–4.29 (m, 1H), 4.08 (dt, J = 7.4, 7.6 Hz, 1H), 3.68–3.48 (m, 12H), 3.40–3.29 
(m, 6H), 3.14 (dt, J = 4.3, 7.6 Hz, 1H), 2.91 (dd, J = 5.0, 12.9 Hz, 1H), 2.73 (d, J = 12.9 Hz, 1H), 2.17 (t, J 
= 7.3 Hz, 2H), 2.10–1.30 (m, 12H), 1.78 (tt, J = 5.9 Hz, 4H), 1.42 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 
172.9, 172.5, 166.9, 163.7 (2C), 163.4, 155.9, 135.1 (2C), 128.5 (2C), 124.1 (2C), 79.6, 77.2, 70.5, 70.4, 
70.1, 70.0, 69.8, 69.5, 62.0, 60.0, 55.7, 54.5, 40.6, 38.9, 37.9, 37.3, 35.8, 32.3, 29.0, 28.8 (2C), 28.4 (3C), 
28.2 (2C), 25.5, 22.9; IR (chloroform) 3362, 3005, 2933, 2870, 1792, 1735, 1704, 1539, 1469, 1456, 1369 
cm
–1
; HRMS (ESI) m/z 900.4174 (calcd for C41H63N7NaO12S [M+Na]
+, Δ –2.1 mmu). 
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Diazirine amide 18.  
 
 
A solution of amide 15 (14.7 mg, 16.7 µmol) in a 1:1 mixture of dry dichloromethane and trifluoroacetic acid 
(1 mL) was stirred for 30 min at 0 °C, and azeotropically concentrated with toluene in vacuo to give crude 
amine trifluoroacetic acid salt. To a stirred solution of the crude amine trifluoroacetic acid salt in dry 
N,N-dimethylformamide (0.5 mL) were added diazirine succinyl ester 17
8
 (11.9 mg, 36.4 µmol) and 
diisopropylethylamine (10 µL, 57 µmol) under a nitrogen atmosphere. After being stirred for 3 h at room 
temperature, the resulting mixture was concentrated. The crude material as purified with a recycling HPLC 
[JAIGEL-1H, JAIGEL-2H ( 20 mm I.D. × 300 mm), chloroform, 3.8 mL/min, UV254 nm] to give diazirine 
amide 18 (13.5 mg, 82%) as a colorless oil. Compound 18: [α]D
25
 +6.3 (c 0.49, chloroform); 
1
H NMR (400 
MHz, CDCl3 ) δ 8.67 (br d, J = 7.8 Hz, 1H), 7.94 (br t, J = 5.5 Hz, 1H), 7.92 (d, J = 8.5 Hz, 2H), 7.85–7.77 
(m, 4H), 7.38 (br t, J = 5.5 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H), 6.98 (br s, 1H), 6.96 (br t, J = 5.5 Hz, 1H), 
4.90 (br s, 1H), 4.71 (d, J = 15.6 Hz, 1H), 4.68 (d, J = 15.6 Hz, 1H) 4.49–4.44 (m, 2H), 4.30 (dd, J = 4.6, 
7.8 Hz, 1H), 3.75–3.26 (m, 18H), 3.04 (dt, J = 4.6, 6.9 Hz, 1H), 2.84 (dd, J = 5.0, 12.8 Hz, 1H), 2.60 (d, J = 
12.8 Hz, 1H), 2.02 (t, J = 7.8 Hz, 2H), 1.80–1.25 (m, 16H); 13C NMR (100 MHz, CDCl3) δ 173.3, 173.0, 
166.95, 166.93, 163.9, 163.8 (2C), 135.3 (2C), 134.8, 132.4, 128.6 (2C), 128.2 (2C), 126.6 (2C), 124.2 (2C), 
77.4, 70.8, 70.4, 70.10, 70.07, 69.9, 69.5, 62.1, 60.1, 55.7, 54.8, 40.7, 38.6, 38.0, 37.0, 35.5, 31.3, 29.3, 28.9, 
28.8, 28.1, 28.0, 25.4, 23.1. Two carbon signals [Ar–C(=N2)CF3] were not detected; IR (chloroform) 3360, 
3004, 2928, 2864, 1792, 1734, 1693, 1656, 1544, 1456, 1345 cm
–1
; HRMS (ESI) m/z 1012.3847 (calcd for 
C45H58F3N9NaO11S [M+Na]
+
 , Δ +2.1 mmu). 
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Alkoxyamine 19 
 
 
 
Diazirine amide 18 (1.4 mg, 1.4 µmol) was dissolved in dry dichloromethane (0.3 mL), and hydrazine 
monohydrate 1.0 µL (21 µmol) was added. After being stirred at room temperature for 10 min, the resulting 
mixture was filtered, and the filtrate was azeotropically concentrated with toluene to give alkoxyamine 19 
(quant. monitored by TLC analysis: Rf 0.23, chloroform–methanol = 4/1), which was immediately used for 
the next step without further purification.  
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ApA-PB (11).  
 
 
 
A solution of ApA (1) (0.32 mg, 300 nmol) in a 3:1 mixture of 1,4-dioxane (150 µL) and 2 M aq. HCl (50 
µL) was stirred for 1 h at 50 °C. The resulting mixture was diluted with sat. sodium hydrogen carbonate aq. 
(250 µL) and water (2 mL) and extracted with chloroform (1 mL × 5). The combined extracts were washed 
with brine and concentrated to give aldehyde 8 (quant. monitored by HPTLC analysis: Rf 0.49, chloroform–
methanol = 9/1), which was used for the next step without further purification.  
A solution of the aldehyde 8 prepared from ApA (0.16 mg, 150 nmol) as described above and the 
alkoxyamine 19 in a 10:1 mixture of ethanol and 50 mM acetate buffer (pH 4.0) (0.22 mL) was stirred at 
room temperature for 22 h under a nitrogen atmosphere. The reaction mixture was directly applied to a 
Develosil ODS-HG-5 HPLC column ( 20 mm I.D. × 250 mm). Samples were eluted with methanol–20 mM 
ammonium acetate (80:20) at a flow rate of 5 mL/min, with monitoring at 254 nm (tR = 49–55 min) to give 
ApA-PB (11) (103 nmol, 69%, based on NMR quantification, E/Z = 7/3 for the C34 isomers). Compound 11: 
1
H NMR (600 MHz, CD3OD) δ 7.97 (d, J = 8.7 Hz, 2H), 7.54 [6.80]
1
 (t, J = 6.0 Hz, 1H), 7.35 (d, J = 8.7 Hz, 
2H), 7.20 (dd, J = 10.8, 15.1 Hz, 1H), 6.38 [6.39]
2
 (dd, J = 10.8, 15.3 Hz, 1H), 6.25–6.20 (m, 1H), 5.97 (br d, 
J = 14.8 Hz, 1H), 5.63 (ddd, J = 4.0, 10.6, 14.8 Hz, 1H), 5.55 (br d, J = 11.2 Hz, 1H), 5.12–5.07 (m, 1H), 
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4.95 (s, 2H), 5.00–4.80 (m, 3 H), 4.79 [4.78]2 (d, J = 10.0 Hz, 1H), 4.48 (dd, J = 4.9, 7.9 Hz, 1H), 4.45 (dd, J 
= 5.3 Hz, 9.0 Hz, 1H), 4.36 [4.44]
1
 (s, 2H), 4.29 (dd, J = 4.4, 7.9 Hz, 1H), 3.70–3.52 (m, 16H), 3.51 (t, J = 
6.0 Hz, 2H), 3.50 (t, J = 6.1 Hz, 2H), 3.38 [3.34]
2
 (s, 3H), 3.38–3.32 (m, 3H), 3.24 (t, J = 6.7 Hz, 2H), 3.21–
3.16 (m, 1H), 3.18 (s, 3H), 3.15 (s, 3H), 3.07 (br d, J = 9.9 Hz, 1H), 2.91 (dd, J = 4,9, 12.7 Hz, 1H), 2.69 (d, 
J = 12.7 Hz, 1H), 2.54–2.25 (m, 5H), 2.38 [2.39]2 (s, 6H), 2.34 [2.34]1 [2.32]3 [2.33]1,3 (s, 6H), 2.17 (t, J = 
7.2 Hz, 2H), 2.20–2.10 (m, 1H), 2.04 [2.04]1 [2.02]3 [2.03]1,3 (s, 3H), 2.10–1.90 (m, 3H), 1.84–1.56 (m, 29H), 
1.50 [1.51]
2
 (s, 3H), 1.30 [1.29]
3
 (d, J = 6.9 Hz, 3H), 1.18–1.06 (m, 3H), 1.04–0.95 (m, 12H), 0.91 (d, J = 
6.9 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H), 0.76 [0.75]
2
 (d, J = 5.8 Hz, 3H). Chemical shifts of the minor 
diastereomers are within brackets: [ ]
1
 7:3 at C34 stereoisomers. [ ]
2
 1:1 at C7 trimethylserine moiety. [ ]
3
 3:1 
at C29 dimethylalanine moiety. HRMS (ESI) m/z 648.3506 (calcd for [C94H152F3N11Na3O22S]/3 [M+3Na]
3+
 , 
Δ +1.3 mmu).  
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ApC (2).  
 
 
 
A solution of ApA (1) (0.65 mg, 600 nmol) in 0.1% triethylamine–methanol (14 mL) was stirred at 50 °C for 
9 days. The reaction mixture was concentrated and applied to a Develosil ODS-HG-5 HPLC column ( 20 
mm I.D. × 250 mm). The fractions eluted with methanol–20 mM ammonium acetate (75:25) at a flow rate of 
5 mL/min, with monitoring at 254 nm gave ApC (2) (245 nmol, 41%, based on NMR quantification, tR =  
43–47 min) and recovered ApA (226 nmol, 38%, tR = 58–63 min) as colorless oils. All of the spectroscopic 
data of 2 prepared from ApA (1) were identical to those of the natural ApC. 
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ApC-PB (12).*                                      *The experiments performed by co-workers.  
 
 
 
ApC-PB (12) was prepared from ApC (2) (170 µg, 179 nmol) and alkoxyamine 19 in 47% yield using the 
same procedure as that for ApA-PB (11). Compound 12: tR = 41–46 min [Develosil ODS-HG-5 ( 20 mm 
I.D. × 250 mm), methanol–20 mM ammonium acetate (80:20), 5 mL/min, UV 254 nm]; 1H NMR 600 MHz, 
CD3OD) δ 7.96 (d, J = 8.5 Hz, 2H), 7.54 [6.80]
1
 (t, J = 6.4 Hz, 1H), 7.34 (d, J = 8.5 Hz, 2H), 7.24 (dd, J = 
10.4, 15.3 Hz, 1H), 6.38 (ddd, J = 5.0, 9.8, 15.0 Hz, 1H), 6.31 (dd, J = 15.0, 10.4 Hz, 1H), 5.92 (d, J = 15.3 
Hz, 1H), 5.65 (ddd, J = 5.0, 10.4, 14.8 Hz, 1H), 5.55 (br d, J = 11.4 Hz, 1H), 5.14 (m, 1H), 5.10 (m, 1H), 
5.00–4.77 (m, 2H), 4.48 (dd, J = 4.4, 7.5 Hz, 1H), 4.46 (dd, J = 4.4 Hz, 8.0 Hz, 1H), 4.39 [4.44]1 (s, 2H), 
4.29 (dd, J = 4.5, 7.8 Hz, 1H), 3.70–3.45 (m, 3H), 3.62-3.49 [4.21-3.95]1 (m, 16H), 3.33 (m, 1H), 3.24 (t, J = 
6.8 Hz, 2H), 3.20 (m, 1H), 3.18 (s, 3H), 3.16 (s, 3H), 3.08 (dd, J = 2.8, 11.6 Hz, 1H), 2.91 (dd, J = 5.0, 12.8 
Hz, 1H), 2.69 (d, J = 12.8 Hz, 1H), 2.47–2.41 (m, 1H), 2.37–2.27 (m, 5H), 2.34 [2.35]1 [2.33]2 [2.33]1,2 (s, 
6H), 2.20–1.95 (m, 9H), 1.93–1.52 (m, 29H), 1.45 (s, 3H), 1.31 [1.30]2 (d, J = 6.7 Hz, 3H), 1.22–1.08 (m, 
3H), 1.01–0.87 (m, 18H), 0.82 (d, J = 5.9 Hz, 3H). Chemical shifts of the minor diastereomer are within 
brackets: [ ]
1
 7:3 at C34 stereoisomers. [ ]
2
 1:1 at C29 dimethylalanine moiety. HRMS (ESI) m/z 885.4984 
(calcd for [C88H142F3N10NaO20S]/2 [M+H+Na]
2+
 Δ –0.2 mmu).  
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Chapter 3. 
Study on the Interaction of Aplyronine A with Tubulin 
 
 
Abstract 
In vitro labeling experiments with photoaffinity biotin probes and tubulin polymerization assay showed that 
ApA synergistically binds to tubulin in association with actin and inhibits tubulin polymerization. Through 
the gel-permeation HPLC analysis, it was revealed that ApA forms a 1:1:1 heterotrimeric complex with actin 
and tubulin heterodimer. 
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3.1. Introduction 
It is known that the primary target protein of ApA (1) is actin. As shown in chapter 2, in situ photoaffinity 
labeling experiments revealed that ApA-PB (11) also specifically binds to tubulin in cells. A lot of 
compounds targeting actin or tubulin have been reported (see chapter 1). To the best of my knowledge, ApA 
(1) is the first small compound which interacts with both actin and tubulin. It is unknown whether ApA (1) 
interacts with both actin and tubulin together. Also it is still unclear how ApA (1) affects cellular functions 
through the interaction with tubulin to exhibit potent antitumor activity. Therefore it is required to analyze 
more detail interactions between ApA (1) and tubulin. Fortunately both purified actin and tubulin are 
commercially available, and their biochemical experiments have been developed.  
In this chapter, study on the interaction of ApA (1) with tubulin was carried out to analyze the binding 
mode among ApA (1), actin and tubulin. In vitro labeling experiments using photoaffinity probes, 
tubulin-polymerization assay and gel-permeation HPLC analysis were examined.  
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3.2. In vitro analysis of the interaction of ApA with tubulin 
3.2.1. Labeling experiments of purified proteins with ApA-PB 
In vitro photolabeling experiments with purified proteins were carried out to investigate specific interactions 
among ApA (1), actin, and tubulin (Figure 3-1). Tubulin and/or actin incubated in the presence of 0.67 M 
ApA-PB (11) for 30 min. After the photoreaction, labeled proteins were detected by WB analysis with HRP 
conjugate streptavidin (Figure 3-2). 
 
Figure 3-1. Outline of in vitro labeling experiments. 
 
ApA-PB (11) formed a covalent bond with actin but not with tubulin alone (lanes 1 and 3). In the presence 
of actin, however, tubulin was photolabeled with ApA-PB (11) and detected as two biotin-labeled protein 
bands (55 and 58 kDa) (lane 3), as with in situ experiments (see figure 2-22). These results revealed that the 
55 kDa protein also derived from - or -tubulin. It was found that actin is necessary for interaction of ApA 
(1) with tubulin, which suggested that ApA-actin complex interact with tubulin to form ternary complex 
(Figure 3-3). Although stoichiometric amounts of tubulin were used, the amount of tubulin photolabeled by 
ApA-PB (11) was far less than that of actin. Photolabeling by ApA-PB (11) might occur at several places 
following the random movement of a flexible diazirine moiety on the ternary complex. Thus it is inferred 
that the aryldiazirine group of ApA-PB (11) is located inside of actin and it is difficult to reach and interact 
with the tubulin. 
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Figure 3-2. In vitro photolabeling experiment of actin and/or tubulin with ApA-PB (11). After photoreaction 
with actin and tubulin, labeled proteins were detected by HRP conjugate streptavidin. 
 
 
 
 
 
Figure 3-3. Actin-ApA complex may interact with tubulin to form the ternary complex. 
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3.2.2. Design, synthesis and biological activities of ApA-DPB 
3.2.2.1. Conformational search of ApA-PB on actin 
The C24−C34 side chain of ApA (1) binds to the hydrophobic cleft between SD 1 and 3 of actin, and the 
aryldiazirine group in ApA-PB (11) is thought to be located inside of actin. To confirm this hypothesis, 
conformational search of ApA-PB (11) on actin were performed using the software MOE (Molecular 
Operating Environment, Chemical Computing Group Inc.). The initial structure of actin-ApA-PB complex 
was constructed by replacing the side chain part of ApA (1) on the X-ray crystal structure of actin-ApA 
complex. Conformational search of ApA-PB (11) was performed at the molecular mechanics level using the 
Amber12-EHT force-field, under the condition that both ApA moiety of ApA-PB (11) and actin were fixed. 
Six representative conformations within 19 kcal/mol of global minimum structure were superposed in figure 
3-4. As expected, the results of conformational search suggested that the diazirine moiety of ApA-PB (11) 
was peripherally located in hydrophobic cleft of SD 1 and 3 of actin. Therefore, it is difficult that the 
diazirine group of ApA-PB (11) binds efficiently to tubulin compared with actin.  
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a) 
 
b) 
 
Figure 3-4. Conformational search of ApA-PB on actin by using MOE. a) Strucuture of ApA-PB (11). The 
bule-colored partial structure is movable in this conformational search. b) In the left, X-ray crystallographic 
structure of actin-ApA complex was shown (PDB code: 1WUA). In the right, six representative 
conformations were superposed in which conformation within 19 kcal/mol of global minimum structure. 
Diazirine groups are shown as pink spheres. Among 941 conformations within 19 kcal/mol of global 
minimum structure, all diazirine groups existed inside the area of representative structures. 
 
  
Actin-ApA complex ApA-PB (11) 
SD 1 
SD 3 
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3.2.2.2. Design of ApA-DPB 
To enhance the flexibility of the photoreacting group and allow it to reach toward the C7 trimethylserine 
ester moiety, that was believed to be important for binding to tubulin, ApA double-PEG-linked photoaffinity 
biotin probe (ApA-DPB, 21) were designed (Figure 3-5). Conformational search of ApA-DPB (21) on actin 
were carried out in the same way of ApA-PB (11). As shown in figure 3-6, the diazirine group of ApA-DPB 
(21) can protrude from the SD 1 and 3 cleft and locate on the wide area of actin surface. Therefore, it was 
expected that the diazirine group of ApA-DPB (21) might be more accessible to tubulin than that of ApA-PB 
(11). In accordance with this hypothesis, ApA-DPB (21) was synthesized and compared with its 
tubulin-binding property with that of ApA-PB (11). 
 
 
Figure 3-5. Structure of ApA-DPB (21). 
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a) 
 
b) 
 
Figure 3-6. Conformational search of ApA-PB on actin by using MOE. a) Strucuture of ApA-PB (12). The 
bule-colored partial structure is movable in this conformational search. b) Six representative conformations 
were superposed in which conformation within 20 kcal/mol of global minimum structure. Diazirine groups 
are shown as pink spheres. Among 224 conformations within 20 kcal/mol of global minimum structure, all 
diazirine groups existed inside the area of representative structures. 
 
ApA-DPB (21)  
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3.2.2.3. Synthesis of alkoxyamine 27 
To synthesize the ApA-DPB (21), alkoxyamine 27 was synthesized (scheme 3-1). First, succinyl ester 23 was 
prepared by condensation of carboxylic acid 22 with N-hydroxysuccinimide (NHS) (84%). Acidic cleavage 
of the Boc group in 15 with TFA followed by coupling with succinyl ester 23 in the presence of DIPEA 
yielded amide 24 (61% in 2 steps). Deprotection of the Boc group in 24 followed by condensation of amine 
25 with succinyl ester 17
1
 gave amide 26 (97% in 2 steps). Finally, deprotection of Phth group in 26 yielded 
alkoxyamine 27 (quant.). 
 
 
Scheme 3-1. Synthesis of alkoxyamine 27. 
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3.2.2.4. Synthesis of ApA-DPB 
Conversion from ApA (1) to aldehyde 8 by the acidic hydrolysis of the enamide group followed by the 
condensation reaction with alkoxyamine 27 gave ApA-DPB (21) (50% in 2 steps) (Scheme 3-2). 
 
 
Scheme 3-2. Synthesis of ApA-DPB (21) 
 
3.2.2.5. Cytotoxicity of ApA-DPB  
The cytotoxicity of ApA-DPB (21) was compared with those of ApA (1) and ApA-PB (11) (Table 3-1). 
Cytotoxicity of ApA-DPB (21) was 50 times less than ApA (1) and 2-fold more than ApA-PB (11). 
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3.2.3. Labeling experiments of purified proteins with ApA-DPB or ApC-PB. 
Labeling experiments using ApA-DPB (21) were performed (Figure 3-7). As expected, ApA-DPB (21) 
increased the amounts of photolabeled tubulins (55 and 58 kDa) and also slightly increased the amount of 
photolabeled actin (lane 3), in comparison to the treatment with ApA-PB (11) (lane 1).  
To investigate whether tubulin specifically interacts with ApA (1), labeling experiments using ApC-PB 
(12) were also performed (lane 2). ApC-PB (12) did not label tubulin even in the presence of actin as well as 
in situ experiments (Figure 2-22). These results suggested that the trimethylserine moiety of ApA (1) plays a 
key role in the interaction with tubulin, and that the potent antitumor activity of ApA (1) is due to the 
interaction with tubulin. 
 
 
 
 
Figure 3-7. Labeling experiments with aplyronine photoaffinity probes. After photoreaction with actin and 
tubulin, labeled proteins were detected by HRP conjugate streptavidin.  
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3.2.4. Tubulin polymerizing assay 
In general, tubulin-interactive agents exhibit antitumor activity through the disruption of polymerization or 
depolymerization of tubulin. In vitro tubulin polymerization assay
2
 was examined to establish whether 
aplyronines affects microtubule assembly. Tubulin was polymerized with 20% glycerol at 37 °C. The 
polymerization of tubulin immediately started and reached plateau after 20 min under this condition (Figure 
3-8. control). When 10 M of vinblastine (VBL), known tubulin-polymerizing inhibitor, was added, 
fluorescent intensity did not increase, which indicated that tubulin did not polymerized. (Figure 3-9). While 
10 M of actin or ApA (1) alone had little effect on in vitro tubulin polymerization, their 1:1 complex (10 
M) delayed nucleation and growth phases and reduced the final polymer mass of tubulin in a 
dose-dependent manner (Figure 3-8). In contrast, the actin-ApC complex (9 M) failed to attenuate 
microtubule growth (Figure 3-9). 
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Figure 3-8. Tubulin polymerization assay. Tubulin was polymerized with 20% glycerol at 37 °C, as 
monitored by an increase in DAPI fluorescence (ex/em 360/450 nm). Values are the mean ±SDs of four 
independent experiments.    
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Figure 3-9. Tubulin polymerization assay. Tubulin was polymerized with 20% glycerol at 37 °C, as 
monitored by an increase in DAPI fluorescence (ex/em 360/450 nm). Values are the mean ±SDs of four 
independent experiments.  
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3.2.5. Analytical ultracentrifugation 
To confirm that ApA (1) inhibit tubulin polymerization in association with actin, ultracentrifugation 
experiments were carried out (Figure 3-10). Polymerized tubulin was precipitated by ultracentrifugation and 
dominantly detected in the precipitate (P) fraction (lanes 1), while depolymerized tubulin was detected in the 
supernatant (S) fraction (lane 2). In the presence of ApA (1) or actin, tubulin was polymerized and detected 
in the P fraction (lanes 3 and 4). Actin was polymerized in this tubulin stabilizing buffer condition and 
precipitated (lane 6), while actin was depolymerized in the presence of ApA (1) and detected in the S fraction 
(lane 7). Thus it was indicate that actin-ApA complex can be formed in this buffer condition. Only upon 
treatment with both ApA (1) and actin, the tubulin was observed mostly in the S fraction along with actin, 
which suggested that actin-ApA complex inhibited the polymerization of tubulin (lane 5). ApA (1), actin and 
tubulin synergistically interact to form ternary complex. 
 
 
 
Figure 3-10. Tubulin sedimentation assay. Tubulin (3 M) was polymerized with paclitaxel (3 M). In lane 2, 
CaCl2 (5 mM) was added instead of paclitaxel to inhibit tubulin polymerization. Proteins in the supernatant 
(S) and the precipitate (P) were analyzed by SDS-PAGE, and detected with CBB stain.  
 
 
  
95 
 
3.3. Analysis of the binding mode of ternary complex 
Experiments of section 3.2. led to the conclusion that ApA and actin synergistically interact with tubulin and 
inhibit tubulin polymerization. Next my question is what kind of the ternary complex was formed to inhibit 
the tubulin polymerization. To analyze and detect the ternary complex, gel-permeation HPLC analysis was 
examined. 
 
3.3.1. Gel-permeation HPLC analysis of ternary complex 
Tubulin, actin and/or ApA were analyzed with gel-permeation HPLC (Figure 3-11). Tubulin was detected as 
a single peak (tR 16.31 min) in the tubulin stabilizing buffer.
3
 The retention time of the peak was compared 
with these of standard proteins (Figure 3-12), which indicated that the molecular weight was 106 kDa, so 
tubulin was eluted as heterodimer (100 kDa). Actin was polymerized in the tubulin stabilizing buffer, so it 
was difficult to analyze actin alone. When a mixture of actin and ApA was analyzed, a single peak (tR 18.24 
min) corresponding to 42.7 kDa was detected suggesting the formation of actin-ApA complex (44 kDa). 
When the actin-ApA complex and tubulin were coanalyzed, a mobility peak (tR 15.42 min) appeared that was 
faster than both tubulin heterodimer and actin-ApA complex peaks, and the latter two were reduced. To 
confirm the peak is a ternary complex, components of the peaks were analyzed by SDS-PAGE. Detection 
with CBB stain and anti-/-tubulin revealed that the faster mobility peak contained both actin and 
/-tubulin. The retention time indicates that the ternary complex corresponded to the 1:1:1 complex of 
actin-ApA-tubulin heterodimer (145 kDa).  
Gel-permeation HPLC analysis with ApC (2) instead of ApA (1) was conducted (Figure 3-13). Ternary 
complex was not detected, and instead, two peaks corresponding to the actin-ApC complex and tubulin 
heterodimer were detected. It was confirmed by SDS-PAGE analysis that these two peaks were the 
actin-ApC complex and tubulin heterodimer, respectively. This result was corresponding to tubulin 
polymerization assay and photolabeling experiments. These results suggested that ApC (2) cannot form the 
ternary complex with actin and tubulin. 
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Figure 3-11. (a) Gel-permeation HPLC analysis of tubulin and/or actin-ApA complex. Column, TSKgel 
SuperSW3000 (ϕ 4.6×300 mm); flow rate, 0.2 mL/min; temp., 8 °C; detection, UV 280 nm.; Elution proteins 
(fractions 1−12) were detected with (b) CBB stain and (c) immunoblotting using anti-/-tubulin. 
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Figure 3-12. Standard curve. Column, TSKgel SuperSW3000 ( 4.6 × 300 mm). Buffer, 50 mM PIPES·K 
(pH 6.8), 100 mM KCl, 10 mM MgCl2. Temp., 8 °C. The column was calibrated using protein standards, and 
a standard curve is shown in the graph.  
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Figure 3-13. (a) Gel-permeation HPLC analysis with ApC. Column, TSKgel SuperSW3000 (ϕ 4.6×300 mm); 
flow rate, 0.2 mL/min; temp., 8 °C; detection, UV 280 nm.; (b) Elution proteins (fractions 1−12) were 
detected with CBB stain. 
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A densitometric analysis of the CBB-stained bands (figure 3-11, b, tubulin + actin + ApA) showed that the 
quantitative ratios of tubulin-actin in lanes 2 and 3 in figure 3-14 were 1.6:1 and 2.7:1, respectively. These 
values were consistent with the calculated value for 1:1 ratios of 100 kDa tubulin heterodimer-43 kDa actin. 
While we have no evidence regarding the stoichiometry of ApA in the ternary complex, it is likely that the 
1:1 actin-ApA complex binds to a tubulin heterodimer on the basis of the x-ray structural analysis of the 
complex. This ternary complex was stable in solution for at least 1 h, despite being in equilibrium with the 
actin-ApA complex and the liberated tubulin heterodimer.  
 
 
 
 
 
 
 
Figure 3-14. Densitometric analysis of the actin and tubulin complex bands (figure 3-10, b, tubulin + actin + 
ApA). The relative protein amounts were shown.   
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3.3.2. Scatchard plot analysis. 
To examine binding modes and strength of the interaction between actin-ApA complex and tubulin 
heterodimer, kinetics analysis was carried out. (Figure 3-15, a). Various concentrations of actin and constant 
concentration of tubulin and ApA were analyzed with gel-permeation HPLC. The peak of ternary complex 
was increased and the peak of tubulin was decreased with increased concentration of actin. The peak of actin 
also appeared when actin concentration was above 0.75 equivalence. Elution proteins were stained with CBB, 
and the concentrations (= [Df]) of actin-ApA complex unbound to tubulin (fr 1–6) were calculated based on 
the densitometry of CBB-stained bands. Also the ratio (= r) of tubulin that forms a ternary complex with 
actin–ApA to the total tubulin was calculated. The Scatchard plot was constructed by plotting the values of 
r/[Df] against r (Figure 3-15, b). The binding constant of the actin-ApA complex to tubulin heterodimer was 
estimated to be 3.0 × 10
6
 M
–1
 on the basis of a Scatchard plot analysis. The r value converges to 
approximately 1, which indicates that the actin-ApA complex binds to tubulin heterodimer to form 1:1 
complex. 
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Figure 3-15. Gel-permeation HPLC analysis. (a) Dose-dependence of actin for the formation of ternary 
complex. Tubulin (27.5 µM for the heterodimer) and ApA (275 µM) were mixed with various concentrations 
of actin (0 to 41.2 µM) before injection. Buffer, 50 mM PIPES·K (pH 6.9), 100 mM KCl, 5 mM DTT, 10 
mM MgCl2. Column, TSKgel SuperSW3000 ( 4.6 × 300 mm). Flow rate 0.2 mL/min., Temp. 12 °C, 
Detection UV 280 nm. (b) Scatchard plot analysis for the ternary complex.  
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3.4. Conclusion 
To analyze the binding mode among ApA, actin, and tubulin, in vitro labeling experiments using 
photoaffinity probes, tubulin-polymerization assay, and gel-permeation HPLC analysis were conducted. 
In vitro photolabeling experiments showed that ApA-PB synergistically bound to tubulin in association 
with actin. In contrast, ApC-PB was failed to bind to tubulin even in the presence of actin. Therefore, It was 
strongly suggested that trimethylserine ester of ApA is essential for the interaction with tubulin.  
To enhance the labeling efficiency of tubulin, ApA-DPB, in which the photoaffinity group was connected 
with a long PEG linker, was synthesized and showed enhancement of labeling efficiently of tubulin. 
 Tubulin-polymerization assay and ultracentrifugation analysis revealed that ApA inhibited 
polymerization of tubulin in the presence of actin.  
When tubulin, actin and ApA were coanalyzed by gel-permeation HPLC, the peak of ternary complex 
was observed. The retention time and SDS-PAGE analysis revealed that the ternary complex corresponded to 
the 1:1:1 complex of actin−ApA–tubulin heterodimer. The binding constant of the actin-ApA complex to 
tubulin heterodimer was estimated to be 3.0 × 10
6
 M
–1
 on the basis of the Scatchard plot analysis. 
These result revealed that ApA synergistically binds to tubulin in association with actin, and inhibits 
tubulin polymerization. To the best of my knowledge, ApA is a first compound that form the ternary complex 
with two cytoskeletal proteins, actin and tubulin.  
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3.5. Experimental  
 
3.5.1. General 
Aplyronine A was isolated from the sea hare by the methods described in chapter 2. Actin and antibodies 
were obtained from commercial suplies. Tubulin was isolated from the porcine brain by the method described.
3
 
Chemicals and solvents were the best grade available and were used as received from commercial sources. 
For bioassay, ApA and its derivatives were stored in DMSO at 1 mM, actin was stored in G-buffer [2 mM 
Tris·HCl (pH 8.0), 0.2 mM CaCl2, 0.2 mM ATP, 0.5 mM 2-mercaptoethanol] at 5 mg/mL, and tubulin was 
stored in RB buffer [100 mM MES (pH 6.8), 0.5 mM MgCl2, 1 mM EGTA] at 11 mg/mL, unless otherwise 
noted. To protect aryl diazirine derivatives from the light, all synthetic and biological experiments with aryl 
diazirine derivatives were conducted with light-shaded glass or plastic equipments, or under a yellow-filtered 
light hood. All of the following experiments that used cell lysate and proteins were performed on ice unless 
otherwise noted. The protein concentration was measured with a Bio-Rad Protein Assay Kit (Bradford’s 
method) with BSA as a standard. 
TLC analysis was conducted on E. Merck precoated silica gel 60 F254 (0.25 mm layer thickness) or 
HPTLC Silica gel 60 WF254. Fuji Silysia silica gels BW-820 MH and FL-60D, Merck Aluminum oxide 90 
standardized, and Nacalai tesque COSMOSIL 75C18-OPN were used for open column chromatography. 
NMR spectra were recorded on a Bruker Biospin AVANCE 600 spectrometer (600 MHz for 
1
H and 150 MHz 
for 
13
C), or a Bruker Biospin AVANCE 400 spectrometer (400 MHz for 
1
H and 100 MHz for 
13
C). Chemical 
shifts are reported in parts per million (ppm) with coupling constants (J) in hertz relative to the solvent peaks, 
δH 3.30 (residual CHD2OD) and δC 49.0 for CD3OD, δH 7.26 (residual CHCl3) and δ C 77.0 for CDCl3, or δH 
2.50 (residual CHD2S(O)CD3) and δC 39.5 for (CD3)2S=O, respectively. For the quantification of minute 
amounts of specimens by 
1
H NMR analyses, benzene (10 mM in CD3OD) was added to the sample solutions 
as a standard (1:60 v/v). Optical rotations were measured with a JASCO DIP-1000 polarimeter. IR spectra 
were recorded on a JASCO FT/IR-230 spectrometer. High-resolution electrospray ionization mass spectra 
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(HR-ESIMS) were measured on a QSTAR Pulsar i spectrometer (Applied Biosystems) or an AccuTOF CS 
spectrometer (JEOL). Matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry 
(MALDI-TOF MS) was performed using a Bruker ultrafleXtreme spectrometer with 
α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix.  
 
3.5.2. Cell culture and cytotoxicity assay.  
Culture of HeLa S3 cells and cytotoxicity assay were conducted as previously described in chapter 2.  
 
3.5.3. In situ photolabeling experiments 
General procedure  
ApA–PB (11) or ApC–PB (12) were added to the HeLa S3 cells in a 6-well plate (80% confluent). For 
competition experiments, ApA was added simultaneously. After incubation for 2 h at 37 °C, the cells were 
cooled on ice and irradiated with UV light (365 nm) for 15 min, using a handheld UV lamp (0.8 mW/cm
2
). 
The culture medium was removed, and the cells were lysed in 200 µL of lysis buffer [10 mM Tris·HCl (pH 
7.4), 0.15 M NaCl, 1% Triton X-100, 10 µg/mL leupeptin]. After the freeze-thawing process, which was 
repeated five times, the lysate were filtered (Millipore 0.45 µm centrifugal filter), and treated with 
NeutrAvidin agarose resin (40 µL, Pierce), equilibrated with lysis buffer. After incubation with a rotator for 1 
h at 4 °C, the resins were washed four times with 0.1% Tween 20 in PBS (PBS-T), three times with 0.1% 
Tween 20 in 1 M KCl, and twice with PBS, then resuspended in 2 × SDS buffer (40 µL, Sigma). The binding 
proteins were eluted by boiling for 5 min at 95 °C. SDS-PAGE was performed by using a precast 10% 
polyacrylamide gel, and the gels were stained with a Silver Stain Kit, Protein (GE Healthcare).  
For immunoblot analyses, proteins in the gels after electrophoresis were transferred to PVDF membranes, 
using the Trans-Blot
® 
SD semi-dry blotting system (Bio-Rad), according to the manufacturer’s instructions. 
After transfection, PVDF membranes were blocked with 0.5% skim-milk in PBS-T. Proteins were detected 
with HRP-conjugated streptavidin (1:3000, cat. no. RPN1231v, GE Healthcare), rabbit polyclonal 
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anti-β-actin (1:200, cat. no. A2066, Sigma), anti-α-tubulin (1:500, cat. no. RB-9281, Thermo) or 
anti-α-tubulin (1:500, cat. no. RB-9249, Thermo). For all primary antibodies, proteins were further treated 
with HRP-conjugated anti-rabbit IgG (1:2000, cat. no. NA934, GE Healthcare). The HRP-conjugated bands 
were visualized with an ECL-prime system (GE Healthcare), and detected by a Fujifilm LAS-4000 MINI 
imaging scanner. Densitometry of Western blots and CBB-stained proteins were performed using ImageJ 
software.  
 
3.5.4. In vitro photolabeling experiments of purified actin and tubulin with aplyronine 
derivatives.  
Actin (0.20 nmol, from rabbit skeletal muscle, Sigma Co.) and/or tubulin (0.10 nmol as a heterodimer) were 
incubated with ApA-PB, ApC-PB or ApA-DPB (0.20 nmol) in 300 µL of BRB80 (Brinkley Reassembly 
Buffer 80) [80 mM PIPES•Na (pH 6.9), 1 mM MgCl2, 1 mM EGTA, 1 mM GTP] for 30 min in a rotator at 
4 °C. The total concentrations of DMSO and G-buffer, derived from actin solutions, were <2.5%, which did 
not significantly affect tubulin dynamics. The resulting mixture was irradiated with UV light (365 nm) for 30 
min on ice, treated with equal volumes of 2 × SDS-buffer, and boiled for 5 min at 95 °C. SDS-PAGE was 
performed using a precast 10% polyacrylamide gel, and the probe-bound proteins were detected with CBB 
stain and HRP-conjugated streptavidin.  
  
3.5.5. In vitro tubulin polymerization assay.   
For the fluorescence-based tubulin polymerization assay,
2
 ×10 samples (5 µL) were added to 50 µL aliquots 
of 2 mg/ml tubulin (20 µM for the heterodimer) in tubulin assay buffer [80 mM PIPES·Na (pH 6.9), 2 mM 
MgCl2, 0.5 mM EGTA, 10 µM DAPI] with 20% glycerol (v/v) cooled on ice, in a half-volume 96-well plate 
according to the manufacturer’s instruction for this assay kit (cat. BK011P, Cytoskeleton Inc.). Tubulin 
polymerization was monitored by the increase in fluorescence (λex/em 360/450 nm) during 30 min at 37 °C, 
using a TECAN Infinite 200
®
 PRO fluorescence microplate reader.  
106 
 
In another assay of microtubule sedimentation (centrifugation method), 3 µM tubulin in BRB buffer was 
ultracentrifuged (150,000 × g, 30 min at 4 °C) to remove oligomeric tubulins. To the supernatants (500 µL) 
were added 2 mM paclitaxel in DMSO (0.75 µL) to induce microtubule formation, and/or 100 µM actin in 
G-buffer (15 µL) and 1 mM ApA (1.5 µL). As a control experiment, 1 M CaCl2 aq. (2.5 µL) was added 
instead of paclitaxel. After incubation for 1 h at 37 °C, samples were ultracentrifuged (150,000 × g, 1 h at 
37 °C). The supernatants (lyophilized) and precipitates were dissolved in 1 × SDS buffer (100 µL) and boiled 
for 5 min at 95 °C. SDS-PAGE was performed using a precast 10% polyacrylamide gel, and the gels were 
stained with a Quick-CBB kit (Wako).  
 
3.5.6. Gel permeation HPLC analysis of the actin–ApA–tubulin complex. 
Actin, aplyronines, and tubulin heterodimer were mixed at a 1:1:1 molar ratio (50 µM each). After 
incubation at room temperature for 10 min, 10 L of the mixture was analyzed by gel permeation column 
chromatography on a TSKgel SuperSW3000 column (4.6 × 300 mm, TOSOH Co.). The components of the 
mixture were eluted with tubulin elution buffer [50 mM PIPES·K (pH 6.8), 100 mM KCl, 10 mM MgCl2]. at 
8 °C, with a flow rate of 0.2 ml/min.
3
 The absorbance of the eluting solution was monitored at 280 nm, and 
fractions were collected for SDS-PAGE analysis and visualized by CBB stain and immunoblotting analysis 
with anti -/-tubulin. The same experiments were repeated for tubulin, actin–ApA or actin–ApC complexes 
alone. 
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3.5.7. Synthesis and spectroscopic data of ApA-DPB.  
Succinyl ester 23.5 
 
 
 
To a stirred solution of carboxylic acid 22 (22.3 mg, 53.0 µmol, commercially available) in dry 
dichloromethane (0.5 mL) were added N-hydroxysuccimide (9.7 mg, 84 µmol) and 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) (15.5 mg, 81 µmol). After being 
stirred at room temperature for 3 h, the reaction mixture was washed with sat. sodium bicarbonate aq. (4 mL 
× 3) and brine, dried with sodium sulfate, and concentrated. The crude material was purified with a SiO2 
column (0.5 g, chloroform–methanol = 1:0 → 99:1 → 0:1) to give succinyl ester 23 (23.1 mg, 84%) as a 
colorless oil. Compound 23: 
1
H NMR (600 MHz, CDCl3) δ 6.51 (br s, 1H), 4.96 (br s, 1H), 3.65–3.51 (m, 
12H), 3.38 (q, J = 6.0 Hz, 2H), 3.20 (br q, J = 6.0 Hz, 2H), 2.98 (t, J = 7.4 Hz, 2H), 2.83 (br s, 4H), 2.57 (t, J 
= 7.4 Hz, 2H), 1.79–1.72 (m, 4H), 1.43 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 169.7, 168.9 (2C), 168.3, 
156.1, 79.0, 70.50, 70.48, 70.2 (2C), 70.0, 69.5, 38.4, 38.3, 30.6, 29.7, 28.7, 28.4 (3C), 26.8, 25.6 (2C); IR 
(CHCl3) 3453, 3388, 3010, 2929, 2874, 1818, 1789, 1742, 1709, 1668, 1511, 1367, 1215, 1210, 1170, 1090, 
992, 856, 647 cm
–1
; HRMS (ESI) m/z 556.2250 (calcd for C23H39KN3O10 [M+K]
+, Δ −1.7 mmu).   
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Double-PEG linked amide 24.  
 
 
 
A solution of amide 15 (20.9 mg, 23.8 µmol) in a 1:1 mixture of dry dichloromethane and trifluoroacetic acid 
(1 mL) was stirred for 30 min at room temperature and azeotropically concentrated with toluene in vacuo to 
give crude amine (26.4 mg) as a trifluoroacetic acid salt. To a stirred solution of the crude amine 
trifluoroacetic acid salt in dry N,N-dimethylformamide (1 mL) were added succinyl ester 23 (23 mg, 45 
µmol) and diisopropylethylamine (DIPEA, 10 µL, 58 µmol) under a nitrogen atmosphere. After being stirred 
for 11 h at room temperature, the mixture was azeotropically concentrated with toluene. The crude material 
was purified by recycling HPLC [JAIGEL-1H, JAIGEL-2H, chloroform] to give double-PEG linked amide 
24 (17.1 mg, 61%) as a colorless oil. Compound 24: [α]D
25
 +2.5 (c 0.57, chloroform); 
1
H NMR (600 MHz, 
DMSO-d6) δ 8.14 (t, J = 5.7 Hz, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.93–7.80 (m, 6H), 7.74 (t, J = 5.6 Hz, 1H), 
6.74 (t, J = 5.7 Hz, 1H), 6.42 (s, 1H), 6.35 (s, 1H), 4.60 (s, 2H), 4.30 (dd, J = 7.8, 5.0 Hz, 1H), 4.15–4.06 (m, 
2H), 3.53–3.41 (m, 18H), 3.44–3.34 (m, 7H), 3.14–3.02 (m, 8H), 2.95 (q, J = 6.7 Hz, 2H), 2.81 (dd, J = 12.4, 
5.1 Hz, 1H), 2.57 (d, J = 12.4 Hz, 1H), 2.40–2.25 (m, 4H), 2.04 (t, J = 7.4 Hz, 2H), 1.71–1.53 (m, 10H), 
1.55–1.38 (m, 6H), 1.36 (s, 9H), 1.33–1.21 (m, 4H); 13C NMR (150 MHz, DMSO-d6) δ 171.9, 171.60, 
171.57, 171.4, 165.7, 162.9 (2C), 162.7, 155.6, 134.9 (2C), 128.5 (2C), 123.4 (2C), 77.4, 75.8, 69.8 (4C), 
69.5 (4C), 68.10, 68.08, 68.05, 68.02, 61.0, 59.2, 55.4, 52.6, 39.9–39.1 (2C, overlapped with the solvent 
signals), 38.3, 37.2, 35.85, 35.80, 35.7, 35.2, 31.4, 30.7, 29.7, 29.4, 29.3, 29.2, 28.6, 28.24 (3C), 28.20, 28.0, 
25.3, 22.9; IR (CHCl3) 3347, 3007, 2929, 2871, 1793, 1734, 1700, 1663, 1529, 1457, 1357, 1245, 1215 cm
-1
; 
HRMS (ESI) m/z 1202.5960 (calcd for C55H89N9NaO17S [M+Na]
+
 , Δ −2.9 mmu).  
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Diazirine amide 26.  
 
 
 
A solution of double-PEG linked amide 24 (9.9 mg, 8.4 µmol) in a 1:1 mixture of dry dichloromethane and 
trifluoroacetic acid (1 mL) was stirred for 30 min at room temperature and azeotropically concentrated with 
toluene in vacuo to give crude amine (12.9 mg) as a trifluoroacetic acid salt. To a stirred solution of the crude 
amine trifluoroacetic acid salt in dry N,N-dimethylformamide (0.4 mL) were added diazirine succinyl ester 
17
1
 (9.6 mg, 29 µmol) and DIPEA (10 µL, 57 µmol) under a nitrogen atmosphere. After being stirred for 1 h 
at room temperature, the mixture was concentrated in vacuo. The crude material was purified by recycling 
HPLC [JAIGEL-1H, JAIGEL-2H, chloroform] to give diazirine amide 26 (10.5 mg, 97%) as a colorless oil. 
Compound 26: [α]D
23
 +3.7 (c 0.19, chloroform); 
1
H NMR (600 MHz, DMSO-d6) δ 8.58 (t, J = 5.6 Hz, 1H), 
8.14 (t, J = 5.7 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 8.3 Hz, 2H), 7.90–7.80 (m, 6H), 7.73 (t, J = 5.6 
Hz, 1H), 7.37 (d, J = 8.3 Hz, 2H), 6.41 (s, 1H) 6.35 (s, 1H), 4.60 (s, 2H), 4.33–4.27 (m, 1H), 4.15–4.06 (m, 
2H), 3.54–3.41 (m, 18H), 3.41–3.28 (m, 9H), 3.14–3.02 (m, 8H), 2.81 (dd, J = 12.4, 5.1 Hz, 1H), 2.57 (d, J = 
12.4 Hz, 1H), 2.39–2.25 (m, 4H), 2.04 (t, J = 7.4 Hz, 2H), 1.74 (qui, J = 6.6 Hz, 2H), 1.70–1.55 (m, 8H), 
1.54–1.36 (m, 6H), 1.36–1.20 (m, 4H); 13C NMR (150 MHz, DMSO-d6) δ 172.3, 172.04, 172.01, 171.9, 
166.1, 165.5, 163.4 (2C), 163.1, 136.6, 135.3 (2C), 130.5, 128.9 (2C), 128.5 (2C), 126.8 (2C), 123.8 (2C), 
122.2 (q, 
1
JC-F = 274 Hz), 76.2, 70.21, 70.18 (2C), 70.16, 69.99, 69.96 (2C), 69.94, 68.6, 68.53, 68.48, 68.45, 
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61.5, 59.6, 55.8, 53.0, 40.5, 40.3, 38.7, 37.2, 36.3, 36.2, 36.1, 35.6, 31.9, 31.1, 29.83, 29.75, 29.66, 29.65, 
29.0, 28.6, 28.48 (q, 
2
JC-F = 40.5 Hz), 28.46, 25.7, 23.3; IR (chloroform) 3360, 3005, 2928, 2871, 1793, 1735, 
1692, 1659, 1539, 1458, 1349, 1235, 1189, 1162, 1126 cm
–1
; HRMS (ESI) m/z 1330.5408 (calcd for 
C59H84F3KN11O16S [M+K]
+, Δ +0.6 mmu).  
 
 
 
 
Alkoxyamine 27.  
 
 
 
Diazirine amide 26 (1.8 mg, 1.4 µmol) was dissolved in a 21 mM solution of hydrazine monohydrate in 
ethanol (1.0 mL, 21 µmol). After being stirred at room temperature for 15 min, the mixture was filtered, and 
the filtrate was azeotropically concentrated with toluene to give alkoxyamine 27 (quant. monitored by TLC 
analysis: Rf 0.23, chloroform/methanol 4:1), which was immediately used for the next step without further 
purification.  
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ApA–DPB (21).  
 
 
 
A solution of ApA (0.32 mg, 300 nmol) in a 3:1 mixture of 1,4-dioxane (150 µL) and 2 M aq. HCl (50 µL) 
was stirred for 1 h at 50 °C. The resulting mixture was diluted with sat. sodium bicarbonate aq. (250 µL) and 
water (2 mL), and extracted with chloroform (1 mL × 5). The combined extracts were washed with brine and 
concentrated to give aldehyde 8 (quant. monitored by HPTLC analysis: Rf 0.49, chloroform–methanol 9:1), 
which was used for the next step without further purification. A solution of the aldehyde 8 and the 
alkoxyamine 27 prepared as above in a 9:1 mixture of ethanol and 50 mM acetate buffer (pH 4.0) (0.3 mL) 
was stirred at room temperature for 118 h. The reaction mixture was directly applied twice to a Develosil 
ODS-HG-5 HPLC column ( 20 mm I.D. × 250 mm). Samples were eluted with methanol–20 mM 
ammonium acetate (80:20) at a flow rate of 5 mL/min, with monitoring at 254 nm (tR = 45–50 min) to give 
ApA–DPB (21) (149 nmol, 50%, based on NMR quantification, E/Z = 5.7:1 for the C34 isomers). The 
purified ApA-DPB (21) was freeze-dried, dissolved in water, and freeze-dried again twice to remove 
remaining ammonium acetate. Compound 21 : 
1
H NMR (600 MHz, CD3OD) δ 7.90 (d, J = 8.4 Hz, 2H), 7.57 
[6.86]
1
 (t, J = 6.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.20 (dd, J = 10.9, 15.3 Hz, 1H), 6.38 [6.38]
2
 (dd, J = 
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10.9, 14.8 Hz, 1H), 6.22 (ddd, J = 4.4, 9.8, 14.8 Hz, 1H), 5.97 (d, J = 15.3 Hz, 1H), 5.64 (ddd, J = 3.9, 10.9, 
14.8 Hz, 1H), 5.55 (d, J = 11.2 Hz, 1H), 5.15–4.55 (m, 5H), 4.48 (dd, J = 4.8, 7.9 Hz, 1H), 4.41 [4.47]1 (s, 
2H), 4.29 (dd, J = 4.5, 8.6 Hz, 1H), 4.21 (dd, J = 4.9, 8.6 Hz, 1H), 3.70–3.45 (m, 2 8H), 3.41–3.07 (m, 15H), 
3.34 [3.33]
2
 (s, 3H), 3.18 (s, 3H), 3.15 (s, 3H), 2.92 (dd, J = 4.9, 12.7 Hz, 1H), 2.70 (d, J = 12.7 Hz, 1H), 
2.55–2.25 (m, 5H), 2.38 [2.39]2 (s, 6H), 2.34 [2.33]3 (s, 6H), 2.20–1.95 (m, 10H), 2.04 [2.05]1 [2.03]3 
[2.04]
1,3
 (s, 3H), 1.90–0.80 (m, 54H), 0.92 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H), 0.77 [0.76]2 (d, J = 
5.8 Hz, 3H). Chemical shifts of the minor diastereomers are within brackets: [ ]
1
 5.7:1 at C34 stereoisomers. 
[ ]
2
 1.8:1 at C7 trimethylserine moiety. [ ]
3
 1.2:1 at C29 dimethylalanine moiety. HRMS (ESI) m/z 741.7487 
(calcd for C108H179F3N13Na2O27 S [M+H+2Na]
3+
 741.7495, Δ −0.8 mmu).  
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Chapter 4. 
Discussions and Conclusions 
 
In this research, to clarify the mode of action of ApA, the author has carried out the identification of new 
target proteins of ApA and the analysis the interaction between ApA and its target proteins.  
In chapter 2, the author searched the target proteins of ApA by using aplyronine biotin probes.  
1) ApA-biocytin and ApA-bio were synthesized by converting the N-methyl enamide moiety of ApA. These 
two probes maintained the both cytotoxicity and actin-depolymerizing activity of ApA, and a known 
target, actin, was affinity-purified by using these probes (described in section 2.2).  
2) By using ApA-bio, 40 kDa and 47 kDa proteins were specifically purified from tumor cell lysate as with 
actin. These proteins were identified as Arp2 and Arp3 (actin-related proteins) (described in section 
2.3.1).  
3) ApA-PB and ApC-PB, which have photoaffinity groups, were synthesized. They did not covalently bind 
to Arp2 or Arp3. Thus, actin-related proteins might indirectly bind to ApA as the ternary adducts of the 
actin-ApA complex or through the oligomeric actin (described in section 2.3.2).  
4) Through in situ photolabeling experiments with ApA-PB, two proteins (55 kDa and 58 kDa) as well as 
actin were specifically labeled. The major constituents of two bands were -/-tubulin. The 58 kDa 
protein was identified as -tubulin which binds with ApA-PB (described in section 2.4). 
In chapter 3, the author analyzed the interaction among tubulin, ApA and actin through the use of in vitro 
experiments. 
1) In vitro photolabeling experiments showed that ApA-PB synergistically binds to tubulin in association 
with actin. In contrast, ApC-PB did not bind to tubulin even in the presence of actin (described in section 
3.2). 
2) Tubulin polymerization assay and ultracentrifugation analysis revealed that ApA inhibits tubulin 
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polymerization in the presence of actin (described in section 3.3).  
3) Through the use of gel-permeation HPLC analysis, it was revealed that ApA forms a 1:1:1 
heterotrimeric complex with actin and a tubulin heterodimer (described in section 3.4). 
 
As described in chapter 1, it has been suggested that ApA does not interact with known molecular targets of 
antitumor agents, such as DNA, microtubules, and cell cycle regulating proteins. The author established that 
ApA interacts with tubulin in association with actin, thereby inhibiting microtubule assembly. To the best of 
my knowledge, there have been no previous reports that small actin-binding agents disturb microtubule 
assembly.  
Now, tubulin has been identified as the second target of ApA. Here the author considers what factors 
were important for the identification of tubulin. Initial pull-down experiments using ApA-bio showed that 
Arp2 and Arp3 were affinity-purified as binding proteins from HeLa S3 cell lysate. However, Arp2 and Arp3 
did not covalently bind to ApA-PB or ApC-PB. It is noted that no tubulin in the cell lysate was photolabeled 
or affinity-purified with ApA-PB. In contrast, in situ photolabeling experiments established that the cellular 
targets of ApA are both actin and tubulin. These critical differences between in vitro and in situ photolabeling 
experiments might be due to the instability of tubulin under the lysis conditions the author used. 
Through the use of in situ photolabeling experiments, it was demonstrated that ApA binds selectively to 
actin and β-tubulin in cells. In contrast to β-tubulin, the amount of affinity-purified -tubulin with ApA-PB 
was similar to that of the control. This result suggests that the tight association of the subunits of the tubulin 
heterodimer need to be dissociated, which is incompatible with gel permeation HPLC analysis. A possible 
explanation is that ApA-PB covalently bound to β-tubulin might destabilize the association of tubulin 
subunits. Alternatively, it is possible that α-tubulin is more labile than β-isomer under the cell lysis or 
affinity-purification conditions we used, which might enhance its dissociation from the resin.  
It was reported by co-workers that the treatment of HeLa S3 cells with 100 pM ApA caused abnormal 
spindle formation and inhibition of mitosis
1
, which finally induce apoptosis in HeLa S3 cells.
2
 These results 
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suggest that ApA affects microtubule assembly in cells. ApA exhibited cytotoxicity at sub-nM concentration. 
The total actin concentration in eukaryotic cell is approximately 100 M,3 and the Kd value for the actin-ApA 
interaction was shown to be 100 nM.
4
 Therefore, most of ApA might be trapped within cells as an actin 
complex at the sub-nM concentration. Based on these information, plausible mode of action of ApA are 
shown in Figure 4-1. First, ApA interacts with actin to form an actin-ApA complex without causing the 
depolymerization of F-actin at sub-nM concentration. Next, the actin-ApA complex might interact with 
tubulin heterodimer to inhibit microtubule dynamics. Finally the inhibition of microtubule dynamics would 
cause cell cycle arrest through the abnormal spindle formation and apoptosis. Compared to the tubulin 
concentration in eukaryotic cells (~20 M),5 the effective concentration of actin-ApA complex would be too 
low to form the ternary complex with a tubulin heterodimer by the complete decomposition of microtubule. 
Generally, vinblastine binds to microtubule ends to prevent further polymerization, and colchicine binds to 
heterodimer which can be incorporate in the microtubule and induce the dynamic instability.
6
 Thus, they 
affect microtubule dynamics even at low concentration. Actin-ApA complex might have the similar 
mechanism that actin-ApA complex or the ternary complex bind to or incorporate in microtubule in order to 
inhibit microtubule dynamics.  
 
 
Figure 4-1. Plausible mode of action of aplyronine A. 
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Dynamics of microtubule and microfilaments regulate the various cellular functions. These dynamics were 
also regulated by various cellular proteins.
7
 A variety of proteins mediates microtubule-actin interactions and 
regulates their dynamics. Among those, mammalian diaphanous-related (mDia) formin proteins not only 
nucleate and assemble linear actin filaments but also directly bind to microtubules and regulate their 
stabilization.
8
 A member of the mDia family, mDia3, associates with the kinetochore and contributes to 
chromosome alignment in the M-phase.
9
 Another F-actin-associated protein, drebrin, binds to EB3 to 
coordinate the F-actin-microtubule interactions responsible for neurogenesis.
10
 It is possible that ApA 
modulates the coordination between the microtubules and actin and affects cytoskeleton dynamics by 
mimicking such microtubule-targeting, actin-binding proteins. 
Thus, ApA represents a relatively rare type of compound, which binds to two different cytoplasmic 
proteins and forms a ternary complex. A lot of actin-targeting agents have been reported and its modes of 
action were still unclear. It is possible that actin-targeting agents also interact with multiple cellular targets 
via protein-protein interactions (PPI). Actin is an abundant cytoplasmic protein and has important roles in 
various cellar functions in cells. The studies of compounds that induce PPI based on the actin interaction 
have potential for the design and development of newly classified pharmacological tools and therapeutic 
agents. The author expected that the studies on ApA pioneer in these studies. 
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